Document:

Amended & Restated Development, License & Supply Agreement

 Exhibit 10.1 
  

			
	 CONFIDENTIAL
	 	EXECUTION COPY

 AMENDED AND RESTATED 
 DEVELOPMENT, 
 LICENSE AND SUPPLY AGREEMENT 
 dated as of July 31, 2006 
 between

 ETHYPHARM, S.A. 
 194 Bureaux de
la Colline 
 92213 Saint Cloud 
 France 
 and 
 RELIANT
PHARMACEUTICALS, INC. 
 110 Allen Road 
 Liberty Corner, New Jersey 07938 
 United States 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 CONFIDENTIAL 
  

 TABLE OF CONTENTS 
  

							
	 	  	 	  	 	  	Page
	1.	  	DEFINITIONS	  	2
			
	2.	  	PRODUCT DEVELOPMENT PROGRAM; CLINICAL DATA; PRODUCT REGISTRATION	  	11
				
		  	2.1	  	Product Development Program; Dosages	  	11
		  	2.2	  	Ownership of Clinical Data	  	11
		  	2.3	  	ETHYPHARM’s Right to RELIANT Clinical Data	  	12
		  	2.4	  	Regulatory Applications and Related Filings	  	12
		  	2.5	  	ETHYPHARM’s Development Responsibilities	  	13
		  	2.6	  	Compliance of Specifications	  	14
			
	3.	  	GRANT OF LICENSE	  	14
				
		  	3.1	  	Grant of License; License Exclusion	  	14
		  	3.2	  	RELIANT Right of First Refusal Regarding License Exclusion Transactions	  	15
		  	3.3	  	Sublicenses	  	16
		  	3.4	  	Minimum Annual Sales Requirement	  	16
		  	3.5	  	Cooperation Regarding Fenofibrate Product Development	  	18
		  	3.6	  	Competing Dosage Forms	  	18
			
	4.	  	COMPENSATION – LICENSE FEES AND MILESTONE PAYMENTS	  	19
				
		  	4.1	  	License Fees	  	19
		  	4.2	  	Milestone Payments	  	19
		  	4.3	  	Method of Payment	  	19
			
	5.	  	DELIVERY OF PRODUCT FOR CLINICAL AND REGULATORY PURPOSES; PRODUCT LAUNCH; ADDITIONAL MANUFACTURING FACILITY	  	20
				
		  	5.1	  	Clinical Formulations and Placebos	  	20
		  	5.2	  	Registration Batches	  	20
		  	5.3	  	Promotion of the Product	  	21
		  	5.4	  	Additional Manufacturing Facility	  	21
		  	5.5	  	RELIANT Third-Party Beneficiary Rights	  	22
		  	5.6	  	RELIANT Step-In Rights Following Supply Failure Event	  	23
		  	5.7	  	Other RELIANT Rights Regarding Supply	  	24
			
	6.	  	OWNERSHIP AND USE OF INTELLECTUAL PROPERTY; DEVELOPMENT OF COMBINATION PRODUCTS	  	25
				
		  	6.1	  	Ownership	  	25

  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 CONFIDENTIAL 
  

							
		 	 6.2
	  	Patents	  	26
		 	 6.3
	  	Notice of Infringement	  	27
		 	 6.4
	  	ETHYPHARM Indemnified Claims	  	27
		 	 6.5
	  	RELIANT Indemnified Claims	  	28
		 	 6.6
	  	Infringement Indemnification by ETHYPHARM	  	29
		 	 6.7
	  	Infringement Indemnification by RELIANT	  	31
		 	 6.8
	  	Third Party Infringement	  	31
		 	 6.9
	  	Termination Resulting From Infringement	  	32
		 	 6.10
	  	Development of Combination Products	  	33
			
	7.	 	MANUFACTURING STANDARDS; REGULATORY COMPLIANCE; SALE AND SHIPMENT OF PRODUCT; RECALL PROCEDURE AND AUDIT RIGHTS	  	34
				
		 	 7.1
	  	Standard of Manufacture	  	34
		 	 7.2
	  	Encapsulation by RELIANT	  	35
		 	 7.3
	  	Purchase and Sale; Acceptance	  	35
		 	 7.4
	  	Delivery Forecast; Reserve Stock of Product	  	36
		 	 7.5
	  	Shipment Costs; Title and Risk of Loss	  	37
		 	 7.6
	  	RELIANT Right of Review; Exception Notice	  	38
		 	 7.7
	  	Notice of Third Party Audit	  	38
		 	 7.8
	  	Notice of Regulatory Action	  	39
		 	 7.9
	  	Recall or Withdrawal	  	40
		 	 7.10
	  	RELIANT Audit Right Regarding Manufacturing Facilities	  	41
		 	 7.11
	  	Records and Accounting by ETHYPHARM	  	42
			
	8.	 	PRICES	  	42
				
		 	 8.1
	  	Prices and Price Change	  	42
		 	 8.2
	  	Payment Terms	  	44
			
	9.	 	ROYALTIES	  	44
				
		 	 9.1
	  	Royalties	  	44
		 	 9.2
	  	Tax Withholding	  	44
			
	10.	 	REPRESENTATIONS AND WARRANTIES OF THE PARTIES	  	45
				
		 	 10.1
	  	Mutual Representations and Warranties of ETHYPHARM and RELIANT	  	45
		 	 10.2
	  	Additional Representations, Warranties and Covenants of ETHYPHARM	  	48
			
	11.	 	 TERM
	  	51
				
		 	 11.1
	  	Basic Term	  	51
		 	 11.2
	  	Sale of Product Following Termination	  	51

  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  
  

 CONFIDENTIAL 
  

							
			
	12.	  	EVENTS OF DEFAULT, REMEDIES AND EFFECTS OF DEFAULT	  	52
				
		  	12.1	  	Events of Default	  	52
		  	12.2	  	Remedies for Breach; Termination	  	53
		  	12.3	  	Technology Transfer	  	53
		  	12.4	  	Right of First Offer In Connection with Divestiture	  	54
			
	13.	  	INDEMNIFICATION AND INSURANCE	  	54
				
		  	13.1	  	Indemnification of RELIANT	  	54
		  	13.2	  	Indemnification of ETHYPHARM	  	54
		  	13.3	  	Notice and Legal Defense	  	55
		  	13.4	  	Insurance	  	55
			
	14.	  	ETHYPHARM RIGHTS IN CANADA AND MEXICO	  	56
				
		  	14.1	  	Reversion of Canadian and Mexican Rights	  	56
		  	14.2	  	ETHYPHARM Right to RELIANT Clinical Data for Canada and Mexico	  	56
		  	14.3	  	Royalties on Sales of Product in Canada and Mexico	  	57
		  	14.4	  	Certain Restrictions on Commercialization in Canada and Mexico	  	58
			
	15.	  	MISCELLANEOUS	  	59
				
		  	15.1	  	Assignment	  	59
		  	15.2	  	Confidentiality	  	60
		  	15.3	  	Exchange of Information	  	61
		  	15.4	  	Force Majeure	  	61
		  	15.5	  	Amendment	  	62
		  	15.6	  	No Implied Waiver	  	62
		  	15.7	  	Choice of Law	  	63
		  	15.8	  	CONSENT TO JURISDICTION; AGENT FOR SERVICE OF PROCESS	  	63
		  	15.9	  	WAIVER OF JURY TRIAL	  	63
		  	15.10	  	Notice	  	64
		  	15.11	  	English Language	  	65
		  	15.12	  	Execution of Additional Documents	  	65
		  	15.13	  	Severability	  	65
		  	15.14	  	Captions	  	65
		  	15.15	  	Counterparts	  	65
		  	15.16	  	Independent Relationship	  	66
		  	15.17	  	Entire Agreement	  	66
		  	15.18	  	Continued Obligation	  	66
		  	15.19	  	Survival	  	66

  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  
  

 CONFIDENTIAL 
  

 THIS AMENDED AND RESTATED DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT, dated as of July 31,
2006, by and between ETHYPHARM S.A., a corporation organized under the laws of France, with its principal offices at 194 Bureaux de la Colline, 92213 Saint Cloud, France (together with its subsidiaries and Affiliates, collectively,
“ETHYPHARM”), and RELIANT PHARMACEUTICALS, INC., a Delaware corporation and the successor-by-conversion to Reliant Pharmaceuticals, LLC, with its principal offices at 110 Allen Road, Liberty Corner, New Jersey 07938, United States
of America (“RELIANT”). Capitalized terms used herein without definition shall have the meanings specified in Section 1 hereof. 
 WITNESSETH THAT: 
 WHEREAS, as of May 7, 2001, Ethypharm S.A., Ethypharm Industries S.A. (which
was subsequently merged into Ethypharm S.A.) and Reliant Pharmaceuticals, LLC (which was subsequently converted into Reliant Pharmaceuticals, Inc.) entered into a Development, License and Supply Agreement, which agreement was subsequently amended,
modified and supplemented pursuant to a letter agreement, dated December 18, 2002, between Ethypharm S.A. and Reliant Pharmaceuticals, LLC, and Amendment No. 1 thereto, dated as of May 24, 2005 between Ethypharm S.A. and Reliant
Pharmaceuticals, Inc. (as so amended, modified and supplemented, the “Original Agreement”); 
 WHEREAS, ETHYPHARM and
RELIANT are also parties a letter agreement, dated August 15, 2005 (the “Supply Side Letter”), relating to certain supply matters under the Original Agreement; and 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 CONFIDENTIAL 
  

 WHEREAS, ETHYPHARM and RELIANT desire to amend and, except for certain exhibits incorporated herein
by reference to exhibits to the Original Agreement, restate the Original Agreement as set forth herein. 
 NOW, THEREFORE, in consideration
of the agreements and covenants hereinafter set forth and intending to be legally bound hereby, the parties hereto covenant and agree as follows: 
  

	1.	DEFINITIONS 

 “Act” shall
mean the United States Federal Food, Drug and Cosmetic Act, 21 U.S.C. §301 et seq., and the regulations promulgated thereunder, in each case as hereafter amended from time to time, and similar legislation in other countries of the
Territory. 
 “Additional Manufacturing Facility” shall have the meaning specified in Section 5.4. 

“Affiliate” means, with respect to any Person, any other Person directly or indirectly controlling, controlled by, or under common
control with, such other Person. For purposes hereof, the term “controlling” (including the terms “controlled by” and “under common control with”), as used with respect to any Person, will mean the
direct or indirect ability or power to direct or cause the direction of management policies of such Person or otherwise direct the affairs of such Person, whether through ownership of at least fifty percent (50%) of the voting securities of
such Person, by contract or otherwise. In addition and not in limitation of the foregoing, the following entities shall be deemed Affiliates of RELIANT: (i) PharmBay Investors, LLC; (ii) Bay City Capital Fund II, L.P. and Bay City Capital
Fund III, L.P.; and (iii) any of the lineal descendants of Nicholas J. Pritzker, deceased, trusts primarily for the benefit of such lineal descendants, entities controlled by such lineal descendants and/or trust for their benefit. 

 

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 2 

 CONFIDENTIAL 
  

 “API” or “Active Pharmaceutical Ingredient” means the raw
non-micronized fenofibrate used in the Product manufactured by a party other than ETHYPHARM or any of its Affiliates. 
 “Applicable
Laws” means all laws, statutes, codes, treaties, ordinances, judgments, decrees, directives, injunctions, orders of any court, arbitrator or Governmental Authority, rules, regulations, interpretations, authorizations and Applicable Permits
of any Governmental Authority applicable to any of the parties hereto, the transactions contemplated hereby and/or the Product. 
 “Applicable Permits” means any waiver, exemption, variance, permit, license, authorization, consent, certification, registration or similar approval (including, without limitation, any NDA), including, without limitation,
product registrations by or of any Governmental Authority required to be obtained or maintained under Applicable Laws in connection with the formulation, development, registration, manufacture, packaging, labeling, import, export, shipment, receipt,
storage, use, pricing or sale of the Product, regardless of the formulation or dosage form thereof, and any ingredient thereof. 
 “Audit” shall have the meaning specified in Section 7.7. 
 “Bulk Product Form” shall
mean the Product in such form which is ready for incorporation by or on behalf of RELIANT into Finished Dosage Form or such other form as may be sold commercially by RELIANT in the Territory. 
 “Business Day” means any day except Saturday, Sunday and any day which shall be a federal legal holiday in the United States or a day on
which banking institutions in the State of New Jersey or Paris, France are authorized or required by law or other government action to close. 
 “Canadian/Mexican Product” shall have the meaning specified in Section 14.3. 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 3 

 CONFIDENTIAL 
  

 “cGMP” shall mean current Good Manufacturing Practices as in effect under the Act
from time to time and similar regulations in other countries under Applicable Laws. 
 “CMC” shall mean the Chemistry and
Manufacturing Controls section of the IND or NDA, as applicable, as then in effect. 
 “Combination Product” shall have the
meaning specified in Section 6.10. 
 “Competing Dosage Form” shall mean fenofibrate monotherapy product marketed by or on
behalf of RELIANT other than the Product in a formulation and dosage form that is substantially similar or identical to the Product. For the purposes of this Agreement, no Combination Product shall be considered a Competing Dosage Form. 

“Confidential Information” means, with respect to any Person (including, without limitation, the parties hereto), all proprietary or
confidential information of such Person (including such Person’s Affiliates and subsidiaries), including, without limitation, any non-public Intellectual Property, Know-How, financial information, procurement requirements, purchasing,
manufacturing, customer or supplier information, business forecasts and plans, financing information, detailing, sales and merchandising, and marketing plans and information, pricing, and accounting policies and procedures of or related to such
Person; provided, however, that Confidential Information shall not include and information that (a) was or becomes generally available to the public other than as a result of an unauthorized disclosure by a party hereto or any of such
party’s subsidiaries, Affiliates, employees, agents or representatives; (b) was or becomes available to a party hereto on a non-confidential basis from a source other than (in the case of future information) any other party hereto (or any
of such party’s subsidiaries, Affiliates, employees, agents or representatives), provided that such source was not known be bound by any agreement to keep such information confidential or otherwise prohibited from 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 4 

 CONFIDENTIAL 
  

 
transmitting the information by a contractual, legal or fiduciary obligation; or (c) is independently developed by any party hereto without the use of
or reference to the Confidential Information of the other party hereto or any of such other party’s subsidiaries or Affiliates. 
 “Contract Manufacturing Agreement” shall have the meaning specified in Section 5.5. 
 “Delivery Forecast” shall have the meaning specified in Section 7.4. 
 “DMF” shall
mean the Drug Master File (together with all subsequent submissions, supplements and amendments thereto, and any materials, documents or information referred to or relied upon thereby) in the United States and any similar files in other countries of
the Territory that relate to the Product. 
 “ETHYPHARM” shall have the meaning specified in the Preamble. 
 “ETHYPHARM Indemnified Claims” shall have the meaning specified in Section 6.4. 
 “ETHYPHARM Indemnified Parties” shall have the meaning specified in Section 13.2. 
 “ETHYPHARM Infringement Indemnitees” shall have the meaning specified in Section 6.5. 
 “ETHYPHARM Infringement Indemnity Cap” shall have the meaning specified in Section 6.6A(a). 
 “Event of Default” shall have the meaning specified in Section 12.1. 
 “Exception Notice” shall have the meaning specified in Section 7.6. 
 “E-US Indemnified Claims” shall have the meaning specified in Section 6.6A(a). 
 “FDA” shall mean the Food and Drug Administration in the United States and similar Governmental Authorities in other countries within
the Territory, including any successor agencies performing comparable functions. 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 5 

 CONFIDENTIAL 
  

 “Finished Dosage Form” means the Product in the form of single dose capsules
containing the formulation and dosage of API as developed by ETHYPHARM and such quantity and type of excipients specified in the Specifications, which shall be labeled and packaged (in high density polyethylene (HDPE) bottles and/or blister packs as
specified by RELIANT) such that it is ready for immediate marketing, sale or other distribution by RELIANT. 
 “Governmental
Authority” means any international, national, domestic, foreign, regional, local or other governmental or regulatory body, agency, authority, court or other authorized Person, including, without limitation, all such Persons having
jurisdiction over the formulation, development, registration, manufacture, packaging, labeling, import, export, shipment, storage, use, pricing or sale of the Product, regardless of the formulation or dosage form thereof, or health and safety
matters generally. 
 “IND” shall mean an Investigational New Drug Application under the Act (together with all subsequent
submissions, supplements and amendments thereto, and any materials, documents or information referred to or relied upon thereby) seeking authorization to commence clinical trials of the Product in humans, and similar applications or filings in the
other countries within the Territory. 
 “Initial Term” shall have the meaning specified in Section 11.1.

 “Intellectual Property” shall mean all patents (including, without limitation, the Patents), copyrights, trademarks,
service marks, service names, trade names, internet domain names, e-mail addresses, applications or registrations for any of the foregoing, or extensions, renewals, continuations or re-issues thereof, or amendments or modifications thereto,
brandmarks, brand names, trade dress, labels, logos, know-how (including, without limitation, the Know-How), show-how, technical and non-technical information, trade secrets, formulae, techniques, 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 6 

 CONFIDENTIAL 
  

 
sketches, drawings, models, inventions, designs, specifications, processes, apparatus, equipment, databases, research, experimental work, development,
pharmacology and clinical data, software programs and applications, software source documents, third-party licenses, and any similar type of proprietary intellectual property right vesting in the owner and/or licensee thereof pursuant to the
applicable laws or regulations of any relevant jurisdiction or under any applicable license or contract, whether now existing or hereafter created, together with all modifications, enhancements and improvements thereto. 
 “Know-How” means any and all proprietary methods, devices, technology, trade secrets, inventions, compositions, designs, formulae,
know-how, show-how, technical and training manuals and documentation and other information, including, without limitation, processes and analytical methodologies used in development, testing, analysis and manufacture, and medical, clinical and
toxicological testing as well as other scientific data of ETHYPHARM, which is related to or used in connection with the Product or any ingredient thereof, and/or the formulation, development, registration, manufacture, packaging, labeling, import,
export, receipt, shipment, storage, use, pricing or sale thereof, whether now known or hereafter developed. 
 “Launch Date”
shall mean, with respect to each country in the Territory, the first date RELIANT [*] in such country. The parties agree that for all purposes under this Agreement the Launch Date for the United States occurred on February 2, 2005. 

“LET Notice” shall have the meaning specified in Section 3.2. 
 “License” shall have the meaning specified in Section 3.1. 
 “License Exclusion Transaction” shall have the meaning specified in Section 3.1. 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 7 

 CONFIDENTIAL 
  

 “NDA” shall mean any New Drug Application under the Act (together with all
subsequent submissions, supplements and amendments thereto, and any materials, documents or information referred to or relied upon thereby) seeking approval to market, sell or otherwise distribute the Product, in any formulation or dosage form, in
the United States, and similar applications or filings in the countries within the Territory. 
 “Net Royalties” means
royalties payable to ETHYPHARM pursuant to the terms of this Agreement, net of any Taxes required to be withheld therefrom. 
 “Net
Sales” means the aggregate amounts invoiced by RELIANT (including, as applicable, RELIANT’s assignees and sublicensees hereunder) for sales of the Product produced using ETHYPHARM Intellectual Property to independent and unrelated
third parties in the Territory, less any and all (a) trade, quantity and cash discounts; (b) commissions, discounts, refunds, rebates, chargebacks, retroactive price adjustments and any other allowances which effectively reduce the net
selling price; (c) returns, bad debts and uncollectible accounts; (d) Taxes collected, charged or otherwise required to be paid by RELIANT (including, as applicable, RELIANT’s assignees and sublicensees hereunder) in respect thereof;
and (e) insurance, freight, warehousing and other transportation and storage costs related to shipment of the Product. 
 “Nonparticipating Party” shall have the meaning specified in Section 6.8. 
 “Original
Agreement” shall have the meaning specified in the Recitals. 
 “Patents” shall mean any issued patents and patent
applications (including, without limitation, any applications or registrations therefor, extensions, renewals, continuations or re-issues thereof, or amendments or modifications thereto) that are currently owned or hereafter acquired or applied for
by ETHYPHARM, which would be infringed by the formulation, development, registration, manufacture, packaging, labeling, import, export, receipt, shipment, 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 8 

 CONFIDENTIAL 
  

 
storage, use, pricing or sale of the Product or any ingredient thereof in the Territory, but for the rights granted to RELIANT by ETHYPHARM under this
Agreement, including but not limited to those patents and patent applications set forth on the Schedule of Patents attached hereto (as may such schedule shall be amended from time to time). 
 “Person” means any individual, partnership, association, joint venture, corporation, limited liability company, trust or Governmental
Authority or other entity. 
 “Product” means a product composed of or containing micronized fenofibrate, in any dosage
form, including encapsulated or bulk beads, granules or similar presentations, including, without limitation, the fenofibrate product developed by ETHYPHARM for RELIANT pursuant to this Agreement and the Product Development Program. 
 “Product Development Program” shall have the meaning specified in Section 2.1. 
 “Recall” shall have the meaning specified in Section 7.9. 
 “Regulatory Applications” shall have the meaning specified in Section 2.4. 
 “RELIANT” shall have the meaning specified in the Preamble. 
 “RELIANT Clinical Data” shall have the meaning specified in Section 2.2. 
 “RELIANT Indemnified Claims” shall have the meaning specified in Section 6.5. 
 “RELIANT Indemnified Parties” shall have the meaning specified in Section 13.1. 
 “RELIANT Infringement Indemnitees” shall have the meaning specified in Section 6.4. 
 “Specifications” means the pharmaceutical formulation, manufacture, delivery, packaging, labeling, import, export, storage, receipt and
shipment specifications for the Product (including Product in Bulk Product Form and Finished Dosage Form) and any excipients set forth on Exhibit A attached to the Original Agreement (as such Exhibit A may have been or may hereafter be
amended or changed from time to time upon the agreement of the parties). 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 9 

 CONFIDENTIAL 
  

 “Supply Failure Event” shall mean a willful breach of this Agreement by ETHYPHARM
that results in the failure of ETHYPHARM to meet its supply obligations for the Product hereunder, or an injunction or similar action or order that prohibits or prevents ETHYPHARM from meeting its supply obligations hereunder in any material
respect, which failure is not cured within thirty (30) days following written notice from RELIANT thereof (including, but not limited to, any willful failure or refusal to supply as a result of or following a change of control of ETHYPHARM).

 “Supply Side Letter” shall have the meaning specified in the Recitals. 
 “Tax(es)” means, with respect to any Person, all federal, state, local, county, foreign and other taxes, assessments or other government
charges, including, without limitation, income, estimated income, gross receipts, profits, business, license, occupation, franchise, capital stock, real or personal property, sales use, transfer, value added, employment or unemployment, social
security, disability, alternative or add-on minimum, customs, duty, excise, stamp, environmental or withholding taxes, including interest, penalties and additions in connection therewith for which such Person may be liable (including any such tax
related to any other Person for which such Person is liable, by contract, as transferee or successor, by law, treaty or otherwise). 
 “Term” shall have the meaning specified in Section 11.1. 
 “Territory” means:
(a) the United States of America, its territories and possessions including without limitation, Puerto Rico; and (b) the Caribbean (including, without limitation, The Bahamas). 
 “Third Party Infringement” shall have the meaning specified in Section 6.8. 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 10 

 CONFIDENTIAL 
  

	2.	PRODUCT DEVELOPMENT PROGRAM; CLINICAL DATA; PRODUCT REGISTRATION 

 2.1 Product Development Program; Dosages. Since the date of the Original Agreement, ETHYPHARM and RELIANT have developed and, as applicable, during the remaining Term of this Agreement shall develop, the
Product consistent with the terms of this Agreement in accordance with product development program set forth on Exhibit B attached to the Original Agreement (the “Product Development Program”), which Exhibit B
specifies the proposed development timetable and each party’s respective responsibilities related to the development of the Product for sale in the Territory, including, without limitation, the preparation and filing of an NDA and the conduct
of clinical trials related to the Product. As part of the Product Development Program, RELIANT established a highest dosage of [*] mg of API per capsule, however, RELIANT, at its option, may develop in collaboration with ETHYPHARM and conduct
clinical trials in respect of other formulations and/or dosage forms of the Product. ETHYPHARM shall develop the formulations and dosage forms of the Product and manufacture the Product in such formulations and dosage forms as shall be requested by
RELIANT or otherwise required to comply with the Act and any applicable NDA and in compliance with the Product Development Program. 
 2.2
Ownership of Clinical Data. Subject to the provisions of Section 2.3, all preclinical, clinical, technical and other information relative to the clinical program, data, analyses, studies or similar information (including, without
limitation, all Intellectual Property) generated or developed by or on behalf of the parties after the date hereof as a result of or in connection with the Product Development Program and the clinical trials conducted by 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 11 

 CONFIDENTIAL 
  

 
[*] hereunder and thereunder (collectively, the “RELIANT Clinical Data”), shall be owned exclusively by [*]. 
 2.3 ETHYPHARM’s Right to RELIANT Clinical Data. The parties agree, that following the issuance of an NDA for the purpose of licensing the
Product and subject to the terms and conditions of this Agreement, ETHYPHARM shall have access to the RELIANT Clinical Data for use outside the Territory on the basis of terms and conditions to be negotiated in good faith between the parties;
provided, however, that the provisions of this Agreement shall not apply to the use by ETHYPHARM of the RELIANT Clinical Data in Canada and Mexico pursuant to Section 14. For the avoidance of doubt, the parties acknowledge and
agree that, except as provided herein, ETHYPHARM shall have no rights in or to any RELIANT Clinical Data until the terms and conditions of access are agreed or in the event that that the NDA is revoked, cancelled, withdrawn or otherwise impaired as
a result of any act or omission by or behalf of ETHYPHARM of the types described in Section 4.4 of the Original Agreement. 
 2.4
Regulatory Applications and Related Filings. All applications, submissions and regulatory filings (together with all documentation, correspondence and other supporting materials related thereto, collectively, the “Regulatory
Applications”) shall be filed and submitted in RELIANT’s name and shall be owned exclusively by RELIANT, and all Applicable Permits issued pursuant thereto shall be in the name of and owned exclusively by RELIANT. RELIANT shall be
responsible for obtaining any and all necessary regulatory approvals from any Governmental Authority under any Applicable Law or Applicable Permit as a result of any changes to the Specifications requested by RELIANT and for reporting any such
modifications to the Specifications to the applicable Governmental Authority as appropriate. 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 12 

 CONFIDENTIAL 
  

 2.5 ETHYPHARM’s Development Responsibilities. ETHYPHARM has heretofore delivered (and, as
applicable, shall prepare and deliver, and shall cause each applicable supplier or other third party (other than RELIANT) involved with the manufacture and packaging of the Product from time to time hereafter to prepare and deliver), to RELIANT and,
as applicable, file or cause to be filed with the appropriate Governmental Authority: (a) the DMF, which shall be filed with FDA for the manufacture of the Product; and (b) the CMC section of the IND and the NDA, all of which shall be
accurate and complete, and in form and substance reasonably satisfactory to RELIANT and suitable for inclusion in the applicable filing. ETHYPHARM shall, at its own cost, cooperate with and assist RELIANT in the preparation, filing and prosecution
of the Regulatory Applications, and shall prepare and deliver such other documents, and take such other actions, as may be necessary or appropriate to apply for, prosecute or obtain any Applicable Permits. All materials to be prepared by or on
behalf of ETHYPHARM hereunder shall be prepared and delivered and, as applicable, filed, in timely manner in accordance with timetable established by the parties hereunder. ETHYPHARM shall provide RELIANT with sufficient opportunity to review and
comment upon all Regulatory Applications or portions thereof prepared by or on behalf of ETHYPHARM prior to their submission to any Governmental Authority. In the event that RELIANT requests any modifications to the Regulatory Applications or
portions thereof required to be prepared by ETHYPHARM hereunder, the parties shall discuss such modifications in good faith; provided, however, that the party in whose name the Regulatory Application is being made shall retain the ultimate
right to determine the contents thereof. In connection with this Agreement, ETHYPHARM shall also provide RELIANT with full access to all of its information and records, including, without limitation, its Intellectual Property and Confidential
Information, related to the Product and its 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 13 

 CONFIDENTIAL 
  

 
formulation, manufacture and packaging (including, without limitation, formulation, development, pharmacology and clinical data regarding the Product, any
ingredient thereof (including fenofibrate)) in order that RELIANT may obtain and maintain the Applicable Permits contemplated by this Agreement and comply with Applicable Law. 
 2.6 Compliance of Specifications. The Specifications shall at all times be in compliance with the requirements of the Act and, in particular, an
NDA applicable to the Product, such that RELIANT shall be entitled to market, sell and distribute the Product in the Territory, and the parties agree to make any changes to the Specifications as may be required to ensure such compliance. 

 

	3.	GRANT OF LICENSE 

 3.1 Grant of License;
License Exclusion. Subject to the terms set forth herein and in consideration for the payments set forth in Sections 4, 8 and 9 hereof, ETHYPHARM hereby grants to RELIANT the exclusive (even as to ETHYPHARM) royalty-bearing
license to all of ETHYPHARM’s Intellectual Property related to the Product to make or have made (except to make or have made the Product in Bulk Product Form), package, develop, import, export, within the Territory, use, distribute, promote,
market, sell and otherwise fully exploit the Product, in whatever formulation or dosage form, within the Territory (the “License”); provided, however, that the License shall not prevent ETHYPHARM from developing,
manufacturing, licensing, promoting and marketing other products containing fenofibrate as the main active pharmaceutical ingredient in the form of microgranules, directly or through third parties, provided that fenofibrate is combined with another
active pharmaceutical ingredient which does not belong to the statin family and for which there is no valid patent in the Territory (a “License Exclusion Transaction”). 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 14 

 CONFIDENTIAL 
  

 3.2 RELIANT Right of First Refusal Regarding License Exclusion Transactions. In the event that
ETHYPHARM desires to enter into or consummate a License Exclusion Transaction, ETHYPHARM agrees that it shall first provide RELIANT with at least [*] days prior written notice of such proposed License Exclusion Transaction specifying the terms and
conditions of the proposed product, product specifications, manufacturing specifications, product development program, license and royalty arrangement and marketing strategy related thereto (each, a “LET Notice”). Following delivery
of any LET Notice, ETHYPHARM shall provide RELIANT with such information as RELIANT may reasonably request in order to allow RELIANT to evaluate the proposed License Exclusion Transaction described therein. Within [*] days following its receipt of
the LET Notice, RELIANT shall have the right, but not the obligation, upon delivery of written notice to ETHYPHARM to agree to enter into the transaction described by the LET Notice upon the terms and conditions stated therein. In the event that
RELIANT notifies ETHYPHARM in writing that it does not wish to exercise its rights under this Section 3.2 or fails to respond to such LET Notice within such [*] day period, ETHYPHARM shall be free to enter into the License Exclusion
Transaction described therein with a third party; provided, however, that ETHYPHARM may not offer to such third party any terms or conditions more favorable to such third party than those described in the LET Notice without first re-offering
such opportunity to RELIANT pursuant to this Section 3.2; provided, further, that in the event ETHYPHARM shall not have entered into a binding agreement with such third party within [*] days following the date of the LET Notice,
ETHYPHARM shall not enter into or consummate such License Exclusion Transaction without re-offering such opportunity to RELIANT pursuant to this Section 3.2. 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 15 

 CONFIDENTIAL 
  

 3.3 Sublicenses. RELIANT shall have the right to sublicense any and all of the rights granted
pursuant to this Agreement, in whole or in part, to one or more Persons; provided, however, that RELIANT shall promptly (a) advise ETHYPHARM of the identity of any such sublicensee; and (b) provide ETHYPHARM with a copy of the
sublicense agreement to establish that such sublicensee has been informed of the obligations under this Agreement. Notwithstanding the foregoing, RELIANT shall not be required to disclose to ETHYPHARM the amount or structure of any royalty or other
payments due to RELIANT from any such sublicensees. RELIANT agrees that it shall require any sublicensees of any of its rights hereunder to preserve the confidentiality of any ETHYPHARM Intellectual Property or Confidential Information to the extent
RELIANT is required to do so under this Agreement. 
 3.4 Minimum Annual Sales Requirement. In order to maintain exclusivity of the
License granted in Section 3.1, RELIANT shall be required to reach minimum annual sales of capsules containing Product (“Minimum Annual Sales”) in the United States as set forth immediately below for the year ending on
the anniversary of the Launch Date in the United States (subject to adjustment for introduction of generic competing products in the Territory as described below); provided, however, that if RELIANT is unable to reach its Minimum Annual Sales
as a result of failure by ETHYPHARM to supply Product, then ETHYPHARM shall not have the right to convert the license to a non-exclusive license and RELIANT shall not be obligated to make any Make-Whole Payment (as defined below) hereunder:

  

			
	 Period (Years Post Launch Date)
	 	 Minimum Number of Capsules to Be Sold

	 February 2, 2005-February 1, 2006
	 	[*]
	 February 2, 2006-February 1, 2007
	 	 [*]

	 February 2, 2007-February 1, 2008
	 	 [*]

	 February 2, 2008-February 1, 2009
	 	 [*]

	 February 2, 2009-February 1, 2010
	 	 [*]

	 February 2, 2010-February 1, 2011
	 	 [*]

	 February 2, 2011-February 1, 2012
	 	 [*]

  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 16 

 CONFIDENTIAL 
  

 No Minimum Annual Sales requirements shall apply after February 1, 2012 or in respect of any sales of the
Product by RELIANT inside the Territory, but outside of the United States. Should RELIANT fail to reach the applicable Minimum Annual Sales target during any applicable twelve-month period, ETHYPHARM, as its sole remedy hereunder, may, upon at least
sixty (60) days prior written notice to RELIANT, convert the exclusive license granted to RELIANT pursuant to Section 3.1 to a non-exclusive license in the Territory; provided, however, that RELIANT shall have the option, but
not the obligation, to make an additional payment (the “Make-Whole Payment”), in addition to any other payments due to ETHYPHARM under Section 9.1 in respect of sales of the Product for said twelve-month period, such
that ETHYPHARM receives an aggregate amount for sales of Product for said twelve-month period that is not less than the amount ETHYPHARM would have received under this Agreement had RELIANT achieved the applicable Minimum Annual Sales target for
said twelve-month period, in which case ETHYPHARM shall have no right to convert the License to a non-exclusive license. For the purpose of calculating the amount of the Make-Whole Payment, RELIANT shall use the [*] per capsule for said applicable
twelve-month period. For the avoidance of doubt, the parties agree and acknowledge that sales of the Product by RELIANT’s sublicensees shall be included for the purposes of determining whether the applicable Minimum Annual Sales target has been
satisfied. The parties agree that in the event that any generic products that compete with the Product are introduced in the Territory during the period while any Minimum Annual Sales targets remain in effect, the applicable Minimum Annual Sales
targets shall be reduced by [*] percent ([*]%) in the year of such introduction (pro rated for generic introductions in the middle 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 17 

 CONFIDENTIAL 
  

 
of the applicable year), by [*] percent ([*]%) in the following year, and by [*] percent ([*]%) for each remaining year thereafter. Notwithstanding any
provision herein to the contrary, in the event that RELIANT shall not have transferred or sublicenced its rights under this Agreement on or prior to December 31, 2006, RELIANT and ETHYPHARM shall negotiate in good faith a mutually agreeable
modification or replacement of this Section 3.4 and/or any terms of this Agreement, as applicable (it being agreed that this provision shall apply solely to RELIANT and not any assignee or sublicensee of RELIANT hereunder). 

3.5 Cooperation Regarding Fenofibrate Product Development. During the term of this Agreement, ETHYPHARM shall provide RELIANT with periodic
updates (not less frequently than semi-annually) regarding its products and product development plans relating to or involving fenofibrate. At RELIANT’s request, the parties shall discuss appropriate access to and/or other rights for RELIANT in
respect of such other products and/or product development plans. Nothing contained in this Section 3.5 is intended to supersede or limit any other rights obligations of the parties under other provisions of this Agreement. 
 3.6 Competing Dosage Forms. RELIANT may not, within [*] years of the first Launch Date in the Territory, develop, have developed, promote,
distribute or market any Competing Dosage Form within the Territory, without the prior written consent of ETHYPHARM; provided, however, that the foregoing restriction shall not prevent RELIANT from developing, having developed, promoting,
distributing or marketing any Competing Dosage Form within the Territory provided that RELIANT pays ETHYPHARM royalties in respect of such Competing Dosage Form in accordance with Section 9 of this Agreement; provided, further,
that should RELIANT decide to develop or have developed any Competing Dosage Form within the Territory, RELIANT shall send ETHYPHARM a written notification of such decision in order to 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 18 

 CONFIDENTIAL 
  

 
enable ETHYPHARM to propose within a maximum period of sixty (60) days from receipt of the written notification a similar or comparable product to the
Competing Dosage Form; provided, further, RELIANT agrees to give ETHYPHARM at least ten (10) days prior written notice of RELIANT’s decision to promote, distribute or market any existing any Competing Dosage Form within the
Territory. For the avoidance of doubt, the parties agree and acknowledge that the restrictions in this Section 3.6 shall not apply to any Combination Product. 
  

	4.	COMPENSATION – LICENSE FEES AND MILESTONE PAYMENTS 

 4.1 License Fees. In consideration of the services by ETHYPHARM to research and develop the Product, pursuant to the License and other rights granted hereunder, RELIANT has previously paid to ETHYPHARM license
fees in the aggregate amount of US$[*]. In addition, RELIANT shall pay an additional US$[*] license fee upon the earlier to occur of (i) such time as cumulative Net Sales (measured from the Launch Date in the United States) exceed US$[*] (in
which case such amount shall be payable at such time as the next payment is due to ETHYPHARM in respect of Net Sales pursuant to Section 9.1 hereof), and (ii) solely in the event that RELIANT sublicenses or makes an assignment of
its rights hereunder, December 31, 2006. 
 4.2 Milestone Payments. In addition to the license fees set forth above, RELIANT has
previously paid to ETHYPHARM milestone payments in the an aggregate amount of US$[*]. 
 4.3 Method of Payment. All payments required
to be paid under this Agreement by RELIANT to ETHYPHARM, or ETHYPHARM to RELIANT, shall be paid in United States dollars by wire transfer of immediately available funds to a dollar-denominated account located in the United States pursuant to written
payment instructions, which shall be delivered to by the 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 19 

 CONFIDENTIAL 
  

 
party entitled to such payment at least five (5) Business Days prior to the date such payment is due. Such payment shall be deemed to have been made
upon the issuance of a federal reference number for the wire transfer of said funds. 
  

	5.	DELIVERY OF PRODUCT FOR CLINICAL AND REGULATORY PURPOSES; PRODUCT LAUNCH; ADDITIONAL MANUFACTURING FACILITY 

 5.1 Clinical Formulations and Placebos. ETHYPHARM shall manufacture, deliver and sell to RELIANT such quantities of validated clinical formulations
of the Product, in such formulations and dosage forms as requested by RELIANT, together with matching quantities of placebos, to enable RELIANT to conduct all clinical trials to be conducted pursuant to the Product Development Program established
hereunder. All Product, regardless of formulation or dosage form, and placebos for use by RELIANT in clinical trials shall be: (a) sold to RELIANT at ETHYPHARM’S actual cost as determined in accordance with Exhibit D attached to the
Original Agreement; and (b) delivered by ETHYPHARM within thirty (30) days of ETHYPHARM’s receipt of RELIANT’s order therefor. 
 5.2 Registration Batches. ETHYPHARM shall manufacture, deliver and sell to RELIANT such quantities of full commercial scale batches of the Product, in such formulations and dosage forms as requested by RELIANT, determined by RELIANT
to be necessary to satisfy requirements under Applicable Law or Applicable Permit (including, without limitation, in connection with the filing and approval of an NDA with the FDA) to market the Product in the United States. All Product, in whatever
formulation, for use by RELIANT to satisfy such requirements shall be: (a) sold to RELIANT at ETHYPHARM’S actual cost as determined in accordance with Exhibit D attached to the Original Agreement; and (b) delivered by ETHYPHARM
within thirty (30) days of ETHYPHARM’s receipt of RELIANT’s order therefor. 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 20 

 CONFIDENTIAL 
  

 5.3 Promotion of the Product. For a period of three (3) years following the first Launch
Date in the United States, RELIANT shall use its commercially reasonable efforts to promote the Product utilizing a sales force consisting of at least one hundred fifty (150) sales representatives. 
 5.4 Additional Manufacturing Facility. On or prior to December 31, 2006, ETHYPHARM shall establish, validate and certify an additional
manufacturing facility at Châteauneuf-en-Thymerais, France for the Product, which facility may be owned by ETHYPHARM or a third party contract manufacturer (such facility, the “Additional Manufacturing Facility”). ETHYPHARM
shall certify in writing to RELIANT that the Additional Manufacturing Facility (and, as applicable, any third party contract manufacturer): (i) has the requisite capacity to satisfy ETHYPHARM’s production, packaging and delivery
obligations, and to meet RELIANT’s order requirements, hereunder with respect to the Product in accordance with the Specifications and the terms and conditions of this Agreement; (ii) complies and will comply with all Applicable Laws and
holds all Applicable Permits necessary for the manufacture and packaging of the Product in compliance with cGMP; and (iii) has and will have the irrevocable right to use all Intellectual Property and Confidential Information of ETHYPHARM
necessary to manufacture and package the Product in any formulation or dosage form required hereunder, in accordance with the Specifications and the terms and conditions of this Agreement. 
 5.4A Validation Batches. In addition to complying with any other requirements or specifications hereunder, any validation batches of the Product
produced at the Additional 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 21 

 CONFIDENTIAL 
  

 
Manufacturing Facility shall be finished and delivered to RELIANT in saleable condition for sale to the trade or as samples, as shall be directed by RELIANT.
RELIANT shall pay for such validation batches in accordance with Section 8.1(a). 
 5.4B Suspension of Certain Activities
Under Supply Side Letter. Provided that ETHYPHARM is in compliance with its supply-related obligations under this Agreement, RELIANT agrees that it shall not pursue commercialization of any Product manufactured pursuant to the terms of the
Supply Side Letter. 
 5.5 RELIANT Third-Party Beneficiary Rights. In the event that ETHYPHARM contracts with any third party (other
than RELIANT or any of RELIANT’s Affiliates) to establish the Additional Manufacturing Facility and to provide the manufacturing services required under Section 5.4 hereof (such contract, a “Contract Manufacturing
Agreement”): (a) ETHYPHARM shall deliver to RELIANT a true and complete copy of such Contract Manufacturing Agreement promptly following the execution thereof; (b) such Contract Manufacturing Agreement shall explicitly provide
that RELIANT is a third party beneficiary thereof with the right to enforce the provisions thereof for its benefit; and (c) such Contract Manufacturing Agreement shall contain such terms and conditions that are consistent with those contained
herein (including, without limitation, the obligation to manufacture, package, sell and deliver Product to RELIANT, and the right of RELIANT to conduct an audit an inspection of the Additional Manufacturing Facility pursuant to
Section 7.10 hereof). The parties agree and acknowledge that the foregoing requirements are necessary in order that RELIANT may be assured that it will continue to be supplied with the Product in accordance with the terms and conditions
of this Agreement, and meet its contractual obligations to various third parties. Notwithstanding the foregoing, RELIANT shall not be required to make any payment or render 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 22 

 CONFIDENTIAL 
  

 
any performance hereunder to any Person other than ETHYPHARM, except as RELIANT may agree in writing. 
 5.6 RELIANT Step-In Rights Following Supply Failure Event. 
 (a) Upon the occurrence of a Supply Failure Event, in the event that RELIANT does not exercise its rights under Section 12,
RELIANT shall have the option to exercise step-in rights and ETHYPHARM shall cooperate with RELIANT in the exercise of such rights. Such step-in rights shall include, without limitation, and to the extent allowable under applicable law and
regulation, ETHYPHARM’s grant to RELIANT of such additional license rights, rights of access, rights of observation and rights of management, direction and control as may be necessary or desirable to enable and permit RELIANT (or RELIANT’s
designee) to attempt to cure or mitigate such Supply Failure Event, to the extent the same is subject to cure or mitigation, and/or otherwise to ensure that supply of the Product shall continue to be available to RELIANT under this Agreement. If
RELIANT uses a designee, RELIANT shall be responsible for such designee’s compliance with the provisions of Section 14.2 (Confidentiality) of this Agreement. The foregoing rights shall apply with respect to any facility at which the
Product (and/or API or any excipient used therein) is manufactured, tested, labeled, encapsulated, stored or otherwise handled, in each case to the extent necessary for RELIANT to preserve and protect supply of the Product as contemplated by this
Agreement. In the event that ETHYPHARM cures the Supply Failure Event subsequent to RELIANT’s exercise of its step-in rights, both ETHYPHARM and RELIANT shall reasonably cooperate to effect a termination of RELIANT’s step-in rights with
respect to such Supply Failure Event in such a manner and at such times so as to minimize the liabilities as a result of such termination. For the avoidance of doubt, RELIANT’s exercise of its step-in rights under this Section 5.6
shall not waive or restrict any 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 23 

 CONFIDENTIAL 
  

 
other rights or remedies of the parties under this Agreement, including, without limitation, RELIANT’s right to terminate this Agreement. 
 (b) In furtherance and not in limitation of the foregoing, in addition to rights provided above, the parties hereby agree that in the
event of a Supply Failure Event, RELIANT shall have the right, without terminating this Agreement, to cause ETHYPHARM to effect the technology transfer as contemplated under Section 12.3. 
 (c) In the event that ETHYPHARM shall cure, or cause to be cured, any Supply Failure Event prior to the exercise by RELIANT of its rights
under this Section 5.6, RELIANT shall cease to have any further rights hereunder in respect of such Supply Failure Event (but shall have rights hereunder with respect to any future Supply Failure Event). 
 5.7 Other RELIANT Rights Regarding Supply. 
 (a) Notwithstanding any provisions herein to the contrary, RELIANT shall, upon reasonable notice to ETHYPHARM, have the right to visit any manufacturing facility at which the Product is manufactured (or to be
manufactured), and to observe the manufacture of the Product(s), not more than twice per year (except as otherwise permitted under Section 5.7(b)). 
 (b) In the event of any event, condition or other occurrence that could reasonably result in the inability of ETHYPHARM to meet its supply
obligations hereunder, ETHYPHARM and RELIANT shall consult and cooperate to address such matter and to ensure ETHYPHARM’s ability to continue to meet such supply obligations. 
 (c) In the event of a shortage of supply of the Product, API and/or any other materials necessary for the manufacture and supply of the
Product, ETHYPHARM shall allocate to RELIANT supply of the Product pro rata in accordance with RELIANT’s firm orders for the 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 24 

 CONFIDENTIAL 
  

 
Product so that RELIANT is treated at least as favorably as any other affected ETHYPHARM customers for such formulation, API and/or any such other materials,
as applicable. 
 (d) Prior to July 31, 2006, ETHYPHARM shall take such actions as are necessary to appoint RELIANT as
its sole and exclusive agent for United States customs purposes relating to matters under this Agreement. 
  

	6.	OWNERSHIP AND USE OF INTELLECTUAL PROPERTY; DEVELOPMENT OF COMBINATION PRODUCT 

 6.1 Ownership. Subject to the terms hereof, including, without limitation, the License and other rights granted by ETHYPHARM to RELIANT hereunder,
all existing and future Intellectual Property of the parties with respect to the Product shall be owned as follows: 
 (a)
other than as provided below or elsewhere in this Agreement, all Intellectual Property owned by any party hereto on the date hereof shall continue to be owned by such party; 
 (b) any Intellectual Property developed, created or discovered solely by ETHYPHARM and subject to the license granted hereunder during the
Term of this Agreement relating to the Product and its manufacturing shall be owned by ETHYPHARM; and 
 (c) any Intellectual
Property developed, created or discovered by or on behalf of RELIANT during the Term of this Agreement relating to any of the clinical development and methods of use of the Product, in any formulation or dosage form, and any Intellectual Property
that is otherwise developed by RELIANT shall be owned by RELIANT. 
 Each party agrees to execute and deliver to the party that owns or is entitled to own
any Intellectual Property hereunder, such instruments of transfer and assignment as may be requested by the owner party to vest fully in such party the ownership rights in said Intellectual Property; 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 25 

 CONFIDENTIAL 
  

 
provided, however, that each party hereto shall be entitled, during the Term of this Agreement, to use and practice any and all Intellectual Property
owned by the other party of the types described in foregoing clauses (a), (b) and (c), without additional payment or royalty, for purposes not inconsistent with this Agreement and in accordance with the terms and conditions hereof. In any
event, RELIANT may not use ETHYPHARM’s Intellectual Property to apply for a patent outside the Territory. Each party shall be free to use and practice its own Intellectual Property in any application not inconsistent with the terms of this
Agreement without the consent of the other and without an obligation to notify the other party of such intended use or to pay royalties or other compensation to the other by reason of such use during the Term of this Agreement and thereafter.

 6.2 Patents. Each party shall be responsible, at its own expense, for filing and prosecuting such patent applications, as it deems
appropriate, and for paying maintenance fees on any patents issuing therefrom, for the term of this Agreement, with respect to inventions owned by it that relate to or are used in connection with the manufacture, packaging, sale or use of the
Product and which are necessary for, used in connection with or otherwise related to the performance of this Agreement by either party hereto. Notwithstanding anything herein to the contrary, ETHYPHARM, at its sole cost and expense, shall continue
to prosecute and maintain each of the Patents and shall keep RELIANT advised of all actions relative to the same. If ETHYPHARM fails to carry out the obligations set forth in this Section 6.2 with respect to the Patents, RELIANT may
carry out such obligations on ETHYPHARM’s behalf at ETHYPHARM’s cost and may set off such cost against any amounts due to ETHYPHARM hereunder thereafter. Each party shall promptly render all necessary assistance reasonably requested by the
other party in applying for and prosecuting patent applications based on 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 26 

 CONFIDENTIAL 
  

 
Intellectual Property owned by such other party under this Agreement. Except as otherwise provided herein, patents covering joint inventions, if any, shall
be owned by the parties jointly, and the parties shall share equally in the expenses of filing for and maintaining such patents and any royalties attributable thereto. ETHYPHARM’s obligations in respect of patents pursuant to this
Section 6.2 shall apply only to those patents used in the manufacture of the Product or otherwise related to the Product or necessary for the full and timely performance of ETHYPHARM’s obligations under this Agreement. 

6.3 Notice of Infringement. If either party shall learn of (a) any claim or assertion that the manufacture, use or sale of the Product
under, or any use of Intellectual Property contemplated by, this Agreement, or any other action taken by either party in performance of its obligations hereunder infringes, misappropriates or otherwise violates the Intellectual Property rights of
any third party, or (b) the actual or threatened infringement, misappropriation or other violation by any third party of the Intellectual Property rights of any party hereto that are the subject of this Agreement, then the party becoming so
informed shall as soon as reasonably practicable, but in all events within fifteen (15) Business Days thereof, notify the other party to this Agreement of such claim or assertion, or actual or threatened infringement, misappropriation or other
violation. 
 6.4 ETHYPHARM Indemnified Claims. In the event that any third party brings or threatens to bring a claim against either
party hereto and/or any of its Affiliates that alleges or demonstrates infringement of such third party’s Intellectual Property rights arising out of, resulting from or otherwise related to (i) the Product, including the formulation, the
manufacture of the Product or the micronization of the API and the non-active ingredients contained therein, or (ii) any ETHYPHARM Intellectual Property used by RELIANT, its Affiliates, sublicensees or 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 27 

 CONFIDENTIAL 
  

 
agents as contemplated by this Agreement (such claims, together, “ETHYPHARM Indemnified Claims”), ETHYPHARM shall defend such action at its
own cost and expense, and shall, at its own cost and expense, indemnify and hold harmless RELIANT and RELIANT’s Affiliates, officers, managers, employees, trustees, representatives, consultants, sublicensees and agents (the “RELIANT
Infringement Indemnitees”) as set forth in Section 6.6 below. With respect to the manufacture (but not the micronization) of the API, in the event that (a) any third party brings or threatens to bring a claim against either
party hereto and/or any of its Affiliates that alleges or demonstrates infringement of such third party’s Intellectual Property rights arising out of, resulting from or otherwise related to the manufacture of the API, and
(b) ETHYPHARM’s supplier of the API fails to defend, indemnify and hold harmless ETHYPHARM from such claim, both parties shall cooperate in the defense of such action and equally bear the cost and expenses thereof (it being agreed, in any
event, that any indemnification or other rights or amounts received by ETHYPHARM from such supplier in respect of or as result of such claim shall be applied to the defense of such claim hereunder). 
 6.5 RELIANT Indemnified Claims. In the event that any third party brings or threatens to bring a claim against either party hereto and/or any of
its Affiliates that alleges or demonstrates infringement of such third party’s Intellectual Property rights arising out of, resulting from or otherwise related to any RELIANT Intellectual Property used by RELIANT, its Affiliates, sublicensees
or agents as contemplated by this Agreement (such claims, together, “RELIANT Indemnified Claims”), RELIANT shall defend such action at its own cost and expense, and shall, at its own cost and expense, indemnify and hold harmless
ETHYPHARM, its Affiliates, officers, managers, employees, representatives, consultants and agents (the “ETHYPHARM Infringement Indemnitees”) as set forth in Section 6.7 below. 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 28 

 CONFIDENTIAL 
  

 6.6 Infringement Indemnification by ETHYPHARM. Notwithstanding any other provisions of this
Agreement, ETHYPHARM will defend, indemnify and hold harmless the RELIANT Infringement Indemnitees from and against any and all liabilities, losses, damages, actions, claims and expenses suffered or incurred by RELIANT Infringement Indemnitees
(including reasonable attorneys’ fees, court costs and expert witnesses’ fees) resulting from any ETHYPHARM Indemnified Claims so long as any such claim does not arise from RELIANT’s breach of this Agreement, or arise from
RELIANT’s negligent or intentionally wrongful conduct (it being expressly understood that RELIANT’s reasonable exercise of its rights hereunder with respect to the use of any ETHYPHARM Intellectual Property in accordance with this
Agreement and RELIANT’s reasonable exercise of its rights hereunder in accordance with this Agreement shall not be deemed a RELIANT’s negligent or intentional wrongful conduct as pertaining to violation of another party’s Intellectual
Property rights). 
 6.6A ETHYPHARM’s Infringement Indemnity Cap. 
 (a) In General. Contingent upon ETHYPHARM’s compliance with its supply-related obligations, including its obligations under
Section 5.4, and notwithstanding any provision herein to the contrary, ETHYPHARM’s liability to the RELIANT Infringement Indemnitees for ETHYPHARM Indemnified Claims relating to third party Intellectual Property protected under
federal or state law of the United States under Sections 6.4 and 6.6 of this Agreement (collectively, the “E-US Indemnified Claims”) shall be limited to the lesser of: (i) [*] percent ([*]%) of the total amount of
any costs of any such defense, indemnity or holding harmless related to such E-US Indemnified Claims; and (ii) [*] payable under Section 9.1 and, as applicable, Section [*] (the lesser of such amount, hereinafter referred to as the
“ETHYPHARM Infringement Indemnity Cap”). In the event that ETHYPHARM has is not in compliance with 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 29 

 CONFIDENTIAL 
  

 
its supply-related obligations, including those under Section 5.4 for any reason at December 31, 2006, then this Section 6.6A(a)
may, in RELIANT’s sole discretion, be deemed null and void, in which case it shall be of no further force or effect; provided, however, that in the event that ETHYPHARM’s failure to comply with such obligations is a result of
force majeure and ETHYPHARM is otherwise in compliance with its supply obligations hereunder, then RELIANT shall not have the right to deem this Section 6.6A(a) null and void during the pendency of such force majeure, not
to exceed ninety (90) days; provided, further, in the event of any discrepancy between the provisions of this Section 6.6A(a) and Section 14.4, the provisions of this Section 6.6A(a) shall control. For
the avoidance of doubt, the parties agree and acknowledge that the ETHYPHARM Infringement Indemnity Cap does not and shall not apply to (A) any ETHYPHARM Indemnified Claims in any jurisdiction outside of the United States, or (B) any other
claims for which any RELIANT Infringement Indemnitees and/or RELIANT Indemnified Parties are entitled to be indemnified by ETHYPHARM under any other provision of this Agreement. 
 (b) RELIANT Assumption and Control of Defense. Notwithstanding any provision herein to the contrary, RELIANT shall have the right
to assume and control the defense of all ETHYPHARM Indemnified Claims, and, at RELIANT’S request, ETHYPHARM will provide complete and timely cooperation with RELIANT in such defense, which cooperation shall be at ETHYPHARM’s sole cost and
expense. 
 (c) ETHYPHARM Waiver of Defenses; Acknowledgement. ETHYPHARM, on behalf of itself and each of its
Affiliates, hereby waives each and every claimed defenses to its obligation to idemnify identified in the letter to RELIANT from the law firm of Baach, Robinson & Lewis PLLC dated January 10, 2005 (the “Claimed
Defenses”) and agrees that it shall not 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 30 

 CONFIDENTIAL 
  

 
hereafter assert, directly or indirectly, any of such Claimed Defenses in an effort to reduce or otherwise limit its obligation to indemnify and hold
harmless RELIANT and/or any of the other RELIANT Infringement Indemnitees under this Agreement or otherwise. In addition, ETHYPHARM hereby acknowledges and agrees that all of RELIANT’s actions related to or in respect of the Product through
May 20, 2005 (and all actions generally consistent therewith) constitute the “reasonable exercise” of RELIANT’s rights under this Agreement. In the event RELIANT voids the liability limitations contained in
Section 6.6A(a) as provided therein, [*] provided, however, that under no circumstances shall RELIANT be required to refund, reimburse or otherwise compensate ETHYPHARM for any amounts paid by ETHYPHARM to RELIANT prior thereto.

 6.7 Infringement Indemnification by RELIANT. Notwithstanding any other provisions of this Agreement, RELIANT will defend, indemnify
and hold harmless the ETHYPHARM Infringement Indemnitees from and against any and all liabilities, losses, damages, actions, claims and expenses suffered or incurred by ETHYPHARM Infringement Indemnitees (including reasonable attorneys’ fees,
court costs and expert witnesses’ fees) resulting from any RELIANT Indemnified Claims so long as any such claim does not arise from ETHYPHARM’s breach of this Agreement, or arise from ETHYPHARM’s negligent or intentionally wrongful
conduct (it being expressly understood that ETHYPHARM’s reasonable exercise of its rights hereunder with respect to the use of any RELIANT Intellectual Property in accordance with this Agreement shall not be deemed ETHYPHARM’s negligent or
intentional wrongful conduct as pertaining to violation of another party’s Intellectual Property rights). 
 6.8 Third Party
Infringement. In the event either party believes that a third party is infringing or otherwise violating any party’s Intellectual Property rights with respect to or related 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 31 

 CONFIDENTIAL 
  

 
to the Product in the Territory (a “Third Party Infringement”), ETHYPHARM and RELIANT shall consult with each other and their respective
counsel in order to develop a strategy for addressing the Third Party Infringement. In the event the parties agree to take legal action to stop the Third Party Infringement, they shall agree upon legal counsel to prosecute such action. Unless the
parties agree upon a different formula for sharing the expenses (including attorney and expert fees) of such action and for sharing any award or settlement, the owner of such Intellectual Property shall bear the costs of such action and shall be
entitled to any award or settlement in respect thereof. In the event that one of the parties does not desire or is otherwise unwilling to participate in the action (the “Nonparticipating Party”), the other shall be free to bring the
action in its own name, at its own expense and retain any award or settlement in its entirety; provided, however, that if such third party infringement adversely affects either party’s rights or obligations hereunder, then the
costs of such action shall be borne by the owner of such Intellectual Property, regardless of which party brings or prosecutes such action. If necessary, the Nonparticipating Party shall join as a party to the suit but shall be under no obligation
to participate except to the extent that such participation is required as the result of being a named party to the suit. The Nonparticipating Party shall offer reasonable assistance in connection therewith at no charge to the other party except for
reimbursement of reasonable out-of-pocket expenses including reasonable attorney’s fees. If either party desires to retain counsel independently, the party may do so, but it shall not relieve the party of its obligations under this
Section 6.8. 
 6.9 Termination Resulting From Infringement. In the event that Intellectual Property belonging to any
party and necessary for, used in connection with or otherwise related to the performance of this Agreement by any party hereto is determined to violate or infringe upon any 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 32 

 CONFIDENTIAL 
  

 
Intellectual Property rights of any third party, and the owner of said Intellectual Property is unable to obtain for itself and the benefit of the other
party and its sublicensees, if any, at no additional cost to said other party and/or any of its sublicensees, a license to use the Intellectual Property upon which the claims for infringement or violation is based, then said other party shall have
the right to terminate this Agreement in addition to any other rights or remedies it may have hereunder or at law or in equity. 
 6.10
Development of Combination Products. RELIANT shall have the right, but not the obligation, to develop and commercialize one or more products in which the API is used in combination with other pharmaceutically active substances (each, a
“Combination Product”); provided, however, that RELIANT shall have no right to use any of ETHYPHARM’s Intellectual Property in connection therewith unless such development is made in cooperation with ETHYPHARM. ETHYPHARM
agrees that, in the event RELIANT desires to develop one or more Combination Products with ETHYPHARM, RELIANT shall have access to ETHYPHARM’s Intellectual Property and applicable personnel for the purposes of developing such Combination
Products and shall grant to RELIANT such additional licenses or other rights as may be necessary or desirable, if any, for RELIANT to develop and commercialize one or more Combination Products on reasonable terms to be negotiated in good faith by
the parties. The parties agree that specific terms and conditions relating to the development, license, manufacture, marketing and sale of any Combination Product developed jointly by RELIANT and ETHYPHARM shall be set forth in a separate agreement
to be negotiated and executed by the parties hereto. 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 33 

 CONFIDENTIAL 
  

	7.	MANUFACTURING STANDARDS; REGULATORY COMPLIANCE; SALE AND SHIPMENT OF PRODUCT; RECALL PROCEDURE AND AUDIT RIGHTS 

 7.1 Standard of Manufacture. Subject to Section 7.2, ETHYPHARM shall manufacture and supply, or cause to be manufactured and supplied
as expressly permitted hereunder, to RELIANT the Product pursuant to orders submitted by RELIANT in accordance with Sections 7.3 and 7.4 hereof. All Product supplied to RELIANT under this Agreement shall: (a) comply with the
Specifications, all Applicable Laws and Applicable Permits; (b) be consistent with the DMF and CMC, and produced in a facility and in a manner compliant with cGMP and all other Applicable Laws; (c) not be adulterated or misbranded within
the meaning of the Act; (d) be manufactured under cGMP conditions at ETHYPHARM’s facility in Grand Quevilly, France or, upon at least thirty (30) days prior written notice to RELIANT, at the Additional Manufacturing Facility in
Châteauneuf-en-Thymerais, France, which facility(ies) shall at all times during such manufacture be an FDA-approved manufacturing facility and shall manufacture, package, label, store and handle the Product in accordance with all Applicable
Laws and Applicable Permits; and (e) be in such formulation and dosage form (e.g., Bulk Product Form or Finished Dosage Form) as requested by RELIANT. All shipments of the Product to be delivered to RELIANT under this Agreement,
regardless of the formulation or dosage form thereof, shall be sampled and analyzed by or on behalf of ETHYPHARM to confirm that it meets the Specifications. ETHYPHARM shall deliver or cause to be delivered to RELIANT with each shipment of the
Product a certificate of analysis stating that the Product in the formulations and dosage forms provided meets the applicable Specifications. ETHYPHARM agrees that neither it nor any third party manufacturer of the Product shall make any changes in
the formulation, manufacture, production, packaging, storage and/or shipment of the Product 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 34 

 CONFIDENTIAL 
  

 
without the specific written prior approval of RELIANT unless expressly required by Applicable Law (including, without limitation, cGMP or the Act), in which
case ETHYPHARM shall notify RELIANT in writing immediately of such change and the reason therefor. The responsibility for the final release of the Product delivered by ETHYPHARM to RELIANT for sale or distribution in the Territory shall remain with
RELIANT. 
 7.2 Encapsulation by RELIANT. Notwithstanding any provision herein to the contrary, RELIANT shall not have any obligation
to purchase the Product in Finished Dosage Form. RELIANT shall have the option to purchase Product in Bulk Product Form so that RELIANT may encapsulate and package the Product, either directly at its own facilitates or using the services of one or
more third parties. In the event that RELIANT elects not to have ETHYPHARM encapsulate and package the Product, ETHYPHARM agrees to provide to RELIANT, at cost, such assistance as may reasonably be requested by RELIANT to facilitate the transfer of
the relevant Confidential Information and Intellectual Property of ETHYPHARM to RELIANT or such third party for the purposes of RELIANT’s or such third party’s encapsulation and packaging of the Product, which assistance shall be provided
for a limited period of time to be reasonably agreed upon between the parties. In the event that RELIANT elects to have a third party encapsulate and package the Product using ETHYPHARM Confidential Information and Intellectual Property, RELIANT
agrees that it shall obtain an agreement from such third party to keep such Confidential Information and Intellectual Property confidential in accordance with the terms of this Agreement. 
 7.3 Purchase and Sale; Acceptance. Subject to the terms hereof, during the Term of this Agreement, ETHYPHARM shall sell and deliver to RELIANT,
and RELIANT shall purchase and accept, the Product pursuant to orders submitted by RELIANT to ETHYPHARM 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 35 

 CONFIDENTIAL 
  

 
in accordance with provisions hereof. All deliveries of Product shall be deemed accepted by RELIANT unless RELIANT shall deliver an Exception Notice to
ETHYPHARM in accordance with Section 7.6 hereof. 
 7.4 Delivery Forecast; Reserve Stock of Product. 
 (a) Delivery Forecast. RELIANT shall deliver to ETHYPHARM, and update at least once per calendar quarter, a twelve (12) month
rolling forecast (the “Delivery Forecast”), which shall specify RELIANT’s estimated order requirements of Product, based on manufacturing batch sizes and multiples thereof, desired formulations and dosage forms (e.g.,
Bulk Product Form or Finished Dosage Form), and required delivery dates and destinations for the Product. Notwithstanding any provision herein to the contrary, the first ninety (90) days of the Delivery Forecast shall be binding upon the
parties. 
 (b) Reserve/Safety Stock of Finished Product. ETHYPHARM shall maintain, or cause to be maintained, a
sufficient reserve/safety stock of Product, in such forms as specified by RELIANT, equal to not less than [*]full batches (based on approximately [*] of API per batch) at no additional cost to RELIANT. RELIANT shall advance to ETHYPHARM the cost of
the API that is necessary to manufacture that portion of the reserve/safety stock equal to [*] percent ([*]%) of most recent annual Delivery Forecast. As the reserve/safety stock is delivered to RELIANT, RELIANT will pay for such in accordance with
this Agreement, after deduction of the API costs. As requested by RELIANT, part or all of the reserve Product stock shall be delivered within thirty (30) days after order to RELIANT’s dock in New Jersey, USA 
 (c) Reserve/Safety Stock of API. ETHYPHARM shall at all times maintain a reserve/safety stock of API (in micronized format) of no
less than (i) [*] kgs of API manufactured by Labochim (Laboratorio Chimico Internazionale S.p.a.) (which amount shall be increased to [*] 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 36 

 CONFIDENTIAL 
  

 
kgs upon the occurrence of a Supply Failure Event, such increased reserve/safety stock minimum to remain in effect for a period of one (1) year
following the cure of such Supply Failure Event), or (ii) following approval of Coprima s.a. (or any other party reasonably acceptable to RELIANT) as an approved manufacturer of API for the Product for sale in the Territory, [*] kgs (which
amount shall be increased to [*] kgs upon the occurrence of a Supply Failure Event, such increased reserve/safety stock minimum to remain in effect for a period of one (1) year following the cure of such Supply Failure Event), or such lesser
amount as RELIANT may direct from time to time, of API manufactured by Coprima or such other approved party; provided, however, that RELIANT shall reimburse ETHYPHARM for the purchase and carrying costs of such API in an amount up to $[*]
upon delivery by ETHYPHARM to RELIANT of proper verification and receipts therefor (and in the event that any such amounts are deducted from RELIANT payments to ETHYPHARM, RELIANT shall promptly reimburse ETHYPHARM for such deducted amounts).

 (d) API Supply Agreement. ETHYPHARM represents and warrants to RELIANT that it has in place (and will maintain
during the Term of this Agreement) one or more written binding long-term supply agreements with an API supplier approved by the FDA to ensure supply of micronized API to ETHYPHARM sufficient to meet ETHYPHARM’s obligations to RELIANT under this
Agreement (including validation and full FDA approval of such API, in each case at ETHYPHARM’s sole expense). 
 7.5 Shipment Costs;
Title and Risk of Loss. All Product to be delivered to RELIANT under this Agreement shall be shipped by ETHYPHARM to RELIANT fully insured against risk of loss, theft, seizure and destruction at ETHYPHARM’s cost. Title and risk of loss with
respect to the all shipments of Product shall pass from ETHYPHARM to RELIANT upon acceptance by 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 37 

 CONFIDENTIAL 
  

 
RELIANT at RELIANT’s dock (currently located in Somerset, New Jersey, USA). In the event of delivery at another location(s) within the Territory as may
be specified by RELIANT or RELIANT’s sublicensee(s), the delivery prices agreed upon between the parties shall be reconsidered in order to take into account the possible increase due to such new location or insurance and transportation costs.

 7.6 RELIANT Right of Review; Exception Notice. RELIANT may conduct its own analyses on each shipment of the Product, in whatever
form, delivered by or on behalf of ETHYPHARM pursuant to this Agreement. RELIANT shall notify ETHYPHARM in writing within [*] days after its receipt of any shipment of Product if the same does not comply with RELIANT’s order, does not meet the
Specifications, is adulterated or misbranded, or is otherwise reasonably determined by RELIANT not to comply with any Applicable Laws or Applicable Permits (each such notice, an “Exception Notice”). Any dispute arising between
ETHYPHARM and RELIANT concerning the conformity of any shipment of Product which cannot be settled between the two parties within [*] days following RELIANT’s delivery of such notice, shall be submitted to an independent expert jointly agreed
to by the parties in good faith. The decision of said expert shall be binding on ETHYPHARM and RELIANT. The charges, including the fees and expenses of the expert relating to any dispute described in this Section 7.6 shall be paid by
ETHYPHARM if the expert declares the delivery not to be in conformity with the provisions hereof or by RELIANT if the expert declares the delivery to be in conformity. 
 7.7 Notice of Third Party Audit. ETHYPHARM shall give RELIANT telephonic notice (with written confirmation) of any pending or threatened audit related to the Product (including, without limitation, the
manufacture, production, sale, distribution, import/export or testing of the Product, in whatever form) by any Governmental Authority or other authorized 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 38 

 CONFIDENTIAL 
  

 
Person, regardless of whether such audit is of ETHYPHARM or any Person (other than RELIANT) with which ETHYPHARM has an agreement related to the Product or
any ingredient thereof or process used in connection with the manufacture thereof, including, without limitation, any suppliers of raw materials used in the manufacture of the Product or any third party engaged by ETHYPHARM to manufacture the
Product, in each case which audit affects or could reasonably be expected to affect the performance of ETHYPHARM’s obligations under this Agreement or otherwise affect RELIANT’s sale or distribution of the Product (each, an
“Audit”); provided, however, that ETHYPHARM shall not be required to give such notice to RELIANT of an Audit by any Person that is conducted in the ordinary course pursuant to an agreement between ETHYPHARM and such Person
and not in response to any suspected violation or non-compliance. ETHYPHARM shall provide any notice to RELIANT required under this Section 7.7 as soon as practicable, but in any event within five (5) Business Days, following the
date ETHYPHARM first becomes aware of such Audit, and shall provide RELIANT with any documentation or other information provided or available to it relating to any such Audit, and shall provide RELIANT reasonable opportunity to review and comment,
prior to submission, any response to such Audit. ETHYPHARM shall keep RELIANT fully apprised of the progress and results of any Audit and shall immediately provide RELIANT with the results of such Audit following its conclusion. 
 7.8 Notice of Regulatory Action. ETHYPHARM shall provide RELIANT with notification of its receipt (or the receipt by any Person with which
ETHYPHARM has an agreement related to the Product, including, without limitation, suppliers of raw materials and contract manufacturers) of any warning, enforcement, penalty, default, non-compliance, notices of violation or any similar letters,
notices, investigations, requests for information or orders from 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 39 

 CONFIDENTIAL 
  

 
or of any Governmental Authority or other authorized Person that relate to the Product, including, without limitation, any list of observations (Form FD
483), Warning Letter, Information Letter, Establishment Inspection Report, Notice of Violation, Regulatory Letter or the like issued by the FDA. ETHYPHARM shall provide any notice to RELIANT required under this Section 7.8 as soon as
practicable, but in any event within twenty-four (24) hours, following the date ETHYPHARM first receives or becomes aware of any such regulatory action, and shall provide RELIANT with any documentation or other information provided or available
to it relating thereto. Notwithstanding anything herein to the contrary, ETHYPHARM maintains sole responsibility for any matter pertaining to such regulatory actions. Reliant shall have the right to review and comment on any responses of ETHYPHARM
to any such regulatory action. 
 7.9 Recall or Withdrawal. ETHYPHARM and RELIANT will each maintain or cause to be maintained such
traceability records as are necessary to permit a recall, withdrawal or field correction of the Product (each, a “Recall”). Each party will give telephonic notice (to be confirmed in writing) to the other within twenty-four
(24) hours of the receipt of any information which indicates a Recall may be necessary. The decision to conduct and the right to control a Recall will be solely that of the then current NDA owner, after appropriate consultation with the other
party. Each party will cooperate fully with the other in connection with any Recall efforts. If any Recall is due to any act or omission of ETHYPHARM, ETHYPHARM will bear the cost of the Recall and replace recalled Product with conforming Product at
no additional charge hereunder and will reimburse RELIANT for all of RELIANT’s reasonable direct costs and expenses actually incurred by RELIANT in connection with the Recall including, but not limited to, direct costs of retrieving Product
already delivered to customers and direct costs and expenses RELIANT is required to pay for notification, shipping and handling charges; provided, however, 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 40 

 CONFIDENTIAL 
  

 
that for each such Recall (a) RELIANT will in good faith consult with ETHYPHARM and, to the extent commercially reasonable, implement ETHYPHARM’s
recommendations on how best to conduct the Recall including, without limitation, the notification and retrieval of Product, and (b) prior to any reimbursement hereunder, RELIANT will provide ETHYPHARM with detailed supporting documentation of
all costs and expenses for which reimbursement is being sought. If a Recall of Product distributed is due to any act or omission of RELIANT, RELIANT will remain responsible for the costs of such Recall and will reimburse ETHYPHARM for all of the
reasonable direct costs and expenses described above actually incurred by ETHYPHARM (if any) in connection with such Recall including, but not limited to, administration of the recall and such other reasonable direct costs as may be reasonably
related to the Recall. RELIANT shall not release any Product in the Territory that has not been duly controlled by RELIANT. 
 7.10
RELIANT Audit Right Regarding Manufacturing Facilities. Upon prior notice to ETHYPHARM and upon a minimum of one (1) month prior notice of the anticipated audit date, ETHYPHARM will permit (and will cause any owner and operator of any
Additional Manufacturing Facility to permit) RELIANT to conduct an inspection and audit, of ETHYPHARM’s or such third party’s manufacturing facilities and operations used in the manufacturing, receiving, sampling, analyzing, storing,
handling, packaging and shipping of Product, including, but not limited to, the receipt, storage and issuance of raw materials, labeling and packaging components and ingredients thereof (including, without limitation, all documentation related
thereto) for the purpose of quality control and to assure compliance with cGMP, Applicable Laws, Applicable Permits and the terms of this Agreement. RELIANT may not conduct an audit hereunder more frequently than once during any twelve
(12) month period; provided, however, that RELIANT may conduct an additional audit(s) in the event there is a 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 41 

 CONFIDENTIAL 
  

 
quality or compliance issue concerning the Product or its manufacture that RELIANT deems in good faith to be material hereunder. RELIANT may conduct such
audit using its own personnel or a third party auditor/inspector and shall conduct such audit, or cause such audit to be conducted, during regular business hours and in such a manner so as to minimize interference with ETHYPHARM’s or any third
party’s operations. ETHYPHARM will provide, and shall cause any applicable third party to provide, RELIANT with access to relevant personnel during the audit and ETHYPHARM will provide a written response to any written audit observations
provided by RELIANT within thirty (30) days of ETHYPHARM’s receipt thereof. 
 7.11 Records and Accounting by ETHYPHARM.
ETHYPHARM will, with respect to each lot of Product produced and manufactured by or on behalf of ETHYPHARM hereunder, for the longer of (a) any period required under Applicable Law or Applicable Permit, and (b) a period of two
(2) years after expiry of the expiration dating of such lot, maintain accurate records of the manufacture and testing of such lot of the Product, including, without limitation, all such records which are required by Applicable Law or pursuant
hereto. Access to such records will be made available by ETHYPHARM to RELIANT during normal business hours upon RELIANT’s reasonable written request. 
  

	8.	PRICES 

 8.1 Prices and Price Change.

 (a) ETHYPHARM shall sell, and RELIANT shall buy, the Product at the following price (subject to adjustment as provided
herein): 
  

							
	 Dosage
	  	 Use
	  	Price per
1000 capsules	  	Price per kg of
Product delivered in
Bulk Product Form
	 130mg
	  	Commercial Sale	  	US$[*]	  	US$[*]
	 130mg
	  	Clinical testing, regulatory approval/compliance, and/or promotional sampling purposes	  	US$[*]	  	US$[*]

  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 42 

 CONFIDENTIAL 
  

							
	 Dosage
	  	 Use
	  	Price per
1000 capsules	  	Price per kg of
Product delivered in
Bulk Product Form
	 43mg
	  	Commercial Sale	  	US$[*]	  	US$[*]
	 43mg
	  	Clinical testing, regulatory approval/compliance, and/or promotional sampling purposes	  	US$[*]	  	US$[*]

 provided, however, that the total number of capsules (or, with respect to Bulk Product Form, total
kilograms) that may be purchased at the price listed above for “Clinical testing, regulatory approval/compliance, and/or promotional sampling purposes” shall not exceed (i) [*] percent ([*]%) of the total number of capsules (or, with
respect to Bulk Product Form, total kilograms) of the Product purchased by RELIANT from the date hereof until December 31, 2007, or (ii) [*] of the total number of capsules (or, with respect to Bulk Product Form, total kilograms) of the
Product purchased by RELIANT in any twelve-month period thereafter. At any time following the third (3rd) anniversary of the Launch Date in the United States (i.e., February 2, 2008), the prices for the Product under this Section 8.1(a) shall be subject to adjustment in accordance with the annual increases
to the index described on Exhibit C attached to the Original Agreement. ETHYPHARM shall provide RELIANT at least ninety (90) days prior written notice of any proposed price increase with such supporting documentation therefor as RELIANT
may reasonably request. RELIANT shall indicate on any order that portion of the Product that is being purchased for clinical testing, regulatory approval and compliance, or promotional sampling purposes. On a quarterly basis, RELIANT shall file a
report with ETHYPHARM reconciling its use of the Product for clinical testing, regulatory approval and compliance, and promotional sampling purposes with Net Sales and accompany that report with a payment of any balance due to ETHYPHARM. The samples
of Product shall not be subject to the Net Royalty payment set forth in Section 9.1. 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 43 

 CONFIDENTIAL 
  

 8.2 Payment Terms. ETHYPHARM shall send to RELIANT an invoice showing the amount due under
Section 8.1 with each shipment. RELIANT shall pay ETHYPHARM the amount due within [*] days of the date of its receipt of the applicable invoice, except to the extent of a bona fide dispute between the parties with respect thereto.

  

	9.	ROYALTIES 

 9.1 Royalties. 

(a) Commencing on the first Launch Date, RELIANT shall pay ETHYPHARM a Net Royalty in an amount equal to [*] percent ([*]%) of Net
Sales in accordance with the provisions of this Agreement. 
 (b) No later than sixty (60) days after the end of each
calendar quarter, RELIANT shall report to ETHYPHARM the Net Sales of the Product sold by RELIANT in the Territory and the Net Royalties due to ETHYPHARM for such period. The payment by RELIANT to ETHYPHARM shall be made within sixty (60) days
after the end of each calendar quarter. RELIANT shall keep and shall require its sublicensees to keep true and accurate books of account and shall keep and maintain such records and documents as are reasonably necessary for ETHYPHARM to determine
the Net Royalties due under this Agreement. 
 9.2 Tax Withholding. All Taxes, if any, levied under any laws or regulations applicable
to the transactions contemplated by this Agreement with respect to payments due to ETHYPHARM hereunder shall be for the account of ETHYPHARM, and if required to be withheld from payments to ETHYPHARM, shall be deducted by RELIANT from such payments
to ETHYPHARM. Receipts, if available, for all such withholdings shall be provided to ETHYPHARM. ETHYPHARM shall be responsible for establishing its right to claim any exemption to such charges or to its withholding, shall keep RELIANT advised in
writing or the 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 44 

 CONFIDENTIAL 
  

 
basis and status of all such exemption claims. ETHYPHARM shall be liable for, and shall indemnify RELIANT for, any penalty, interest or other assessment
against RELIANT for failure to pay or withhold such charges in reliance on any such exemption claim or other advice or instructions of ETHYPHARM. 
  

	10.	REPRESENTATIONS AND WARRANTIES OF THE PARTIES 

 10.1 Mutual Representations and Warranties of ETHYPHARM and RELIANT. Each of ETHYPHARM and RELIANT hereby represents and warrants to the other party as follows: 
 (a) Organization. Such party is duly organized, validly existing and in good standing under the laws of the jurisdiction of
incorporation or organization. Such party has the requisite legal and company power and authority to conduct its business as presently being conducted and as proposed to be conducted by it and is duly qualified to do business in those jurisdictions
where its ownership of property or the conduct of its business requires. 
 (b) Authority. Such party has all requisite
legal and company power and authority to enter into this Agreement and to perform the services contemplated hereunder (including, in the case of ETHYPHARM, the manufacture and packaging of the Product, and the grant of the License hereunder). All
company actions on the part of such party, the boards of director or managers, conseils d’administration or similar governing body of such party and the equity holders of such party necessary for (i) the authorization, execution,
delivery and performance by such party of this Agreement, and (ii) the consummation of the transactions contemplated hereby, have been duly taken. 
 (c) Binding Obligation. This Agreement is a legally valid and binding obligation of such party, enforceable against such party in accordance with its terms (except in all cases as such enforceability may be
limited by applicable bankruptcy, insolvency, 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 45 

 CONFIDENTIAL 
  

 
reorganization, moratorium, or similar laws affecting the enforcement of creditors’ rights generally and except that the availability of the equitable
remedy of specific performance or injunctive relief is subject to the discretion of the court before which any proceeding may be brought). 
 (d) No Conflicts. None of the execution and delivery of this Agreement, the consummation of the transactions provided for herein or contemplated hereby, or the fulfillment by such party of the terms hereof or
thereof, will (with or without notice or passage of time or both) (i) conflict with or result in a breach of any provision of the certificate or articles of incorporation or formation, by-laws, statutes, operating agreement or other governing
documents of such party, (ii) result in a default, constitute a default under, give rise to any right of termination, cancellation or acceleration, or require any consent or approval (other than approvals that have heretofore been obtained) of
any Governmental Authority or under any of the terms, conditions or provisions of any material note, bond, mortgage, indenture, loan, arrangement, license, agreement, lease or other instrument or obligation to which such party is a party or by which
its assets may be bound, or (iii) violate any law or regulation applicable to such party or any of its assets. 
 (e)
Insurance. Such party has in full force and effect casualty and liability insurance policies issued by issuers of internally-recognized responsibility and of such types and in such coverage amounts as customary for such party’s business
and consistent with industry standards. 
 (f) Legal Proceedings. There is no action, suit, proceeding or investigation
pending or, to such party’s knowledge, currently threatened, against such party or any other Person that questions the validity of this Agreement or the right of such party to enter into this 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 46 

 CONFIDENTIAL 
  

 
Agreement, or to consummate the transactions contemplated hereby, nor does such party have knowledge that there is any basis for the foregoing. Such party is
not a party or subject to the provisions of any order, writ, injunction, judgment or decree of any Governmental Authority, which would adversely affect its rights or obligations hereunder or the transactions contemplated hereby. 
 (g) Consents and Approvals. All material consents, approvals, qualifications, orders or authorizations of, filings with, or notices
to any Governmental Authority or any other Person required in connection with such party’s execution, delivery or performance of (i) this Agreement, and (ii) the consummation of any other transaction contemplated on the part of such
party hereby have been obtained, made or given. 
 (h) No Violation of Law; Permits. Such party is not in violation of
any law or regulation (nor is such party aware of any violation of any law or regulation by any other Person), which violation could reasonably be expected to adversely affect such party’s performance of its obligations hereunder or the ability
of the other party to realize the intended benefits to such other party under this Agreement, and, except as otherwise contemplated hereby, such party holds each of the licenses, permits, approvals or authorizations necessary with respect to its
current business and operations (and its rights and obligations contemplated hereby) in compliance with all laws and regulations. 
 (i) No Broker. Such party has not retained any finder, broker, agent, financial advisor or other intermediary in connection with the transactions contemplated by this Agreement. 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 47 

 CONFIDENTIAL 
  

 10.2 Additional Representations, Warranties and Covenants of ETHYPHARM. ETHYPHARM hereby
further represents, warrants and covenants to RELIANT, as of the date hereof and during the Term of this Agreement, as follows: 
 (a) Product Compliance; Title. All Product to be manufactured and delivered to RELIANT pursuant to this Agreement, in whatever formulation, dosage form or packaging, will: (i) conform to the applicable Specifications;
(ii) comply with all Applicable Laws and Applicable Permits (and shall not be adulterated or misbranded within the meaning of the Act); (iii) be manufactured under cGMP conditions in an FDA-approved manufacturing facility in accordance
with all Applicable Laws and Applicable Permits, and (iii) upon delivery to RELIANT, good title to such Product will convey to RELIANT and such conveyance will be free and clear of any security interest, other lien or encumbrance. 

(b) Permits. ETHYPHARM has and will maintain during the Term of this Agreement all Applicable Permits and such other permits,
licenses and other authorizations required under Applicable Laws to permit ETHYPHARM to continue to manufacture and package the Product, including, without limitation, the Product in Bulk Product Form and Finished Dosage Form. 
 (c) No Investigation. There is no pending, and ETHYPHARM has no knowledge of any threatened, claim, investigation, proceeding, suit
or other legal, regulatory or similar action asserting that the use, manufacture, packaging, distribution or sale of the Product constitutes an infringement of any Intellectual Property rights of any Person, including, without limitation, any extant
patents, trade secrets, trademarks or other rights of any Person. 
 (d) Intellectual Property. ETHYPHARM (i) is
the sole owner of, and has all rights necessary to use and license to RELIANT, each of the Patents identified on Schedule 1.42 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 48 

 CONFIDENTIAL 
  

 
and such Patents are the only patents required for ETHYPHARM to perform its obligations hereunder; (ii) is the sole owner of, and has all rights
necessary to use and license to RELIANT, all Intellectual Property (other than the Patents) required for ETHYPHARM to perform its obligations hereunder; (iii) has not granted or transferred to, or allowed the use by, any Person in the Territory
of any Intellectual Property owned or licensed by ETHYPHARM which is used in or relates to the manufacture or packaging of the Product; 
 (e) Product Related Intellectual Property. (i) ETHYPHARM owns or possesses adequate licenses or other Intellectual Property and Confidential Information used or held for use in connection with the Product
that are necessary to permit ETHYPHARM to discharge its obligations under this Agreement with respect to the Products, including, without limitation, granting the rights and licenses granted to RELIANT under this Agreement, free and clear of any
liens, licenses, obligations, transfer agreements, transfer restrictions, enforceable claims, royalties or encumbrances that would prevent ETHYPHARM from discharging its obligations under this Agreement with respect to the Product, and
(ii) ETHYPHARM is unaware of any assertion or claim challenging the ownership, use or validity of any of the foregoing. Any licenses associated with the ETHYPHARM Intellectual Property related to the Product are valid and binding and are
enforceable in accordance with their respective terms, and there are no material breaches or defaults thereunder. To the extent that any of the Patents are not owned by ETHYPHARM, such Patents are owned by an Affiliate of ETHYPHARM, and ETHYPHARM
licenses or has the right to use such from such Affiliate of ETHYPHARM. ETHYPHARM will not take any action to terminate, and ETHYPHARM will prevent its Affiliates from taking any action to terminate, any license or grants of rights from an Affiliate
of ETHYPHARM to 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 49 

 CONFIDENTIAL 
  

 
ETHYPHARM with respect to the Patents. ETHYPHARM has the right to grant to RELIANT all of the rights and licenses granted to RELIANT under this Agreement.

 (f) No Infringement. The manufacture, use or sale of the Product by ETHYPHARM or the use of the ETHYPHARM
Intellectual Property by RELIANT to develop, promote, market and sell the Product in the Territory do not, and to ETHYPHARM’s knowledge will not, infringe any valid rights of any third party including inter alia Intellectual Property
rights. The manufacture, use or sale of any raw materials supplied to or otherwise used by ETHYPHARM with respect to the Product do not, and to ETHYPHARM’s knowledge will not, infringe any valid rights of any third party including inter
alia Intellectual Property rights. To ETHYPHARM’s knowledge, ETHYPHARM is unaware of any third party infringement of the Intellectual Property rights relating to the Product. 
 (g) Adverse Drug Experiences. ETHYPHARM has informed RELIANT of all relevant adverse drug experiences related to the Product of
which it has knowledge. 
 (h) Expertise. ETHYPHARM has, and will at all times during the term of this Agreement have,
the requisite expertise, experience and skill to perform its obligations hereunder. 
 (i) Labor Matters. There is no
strike or other labor dispute involving ETHYPHARM or any of its employees pending, or to the knowledge of ETHYPHARM, threatened. With respect to the foregoing, individual and unrelated personnel claims or actions do not constitute a labor dispute.

 (j) No Debarment. Neither ETHYPHARM nor any Person employed or engaged by ETHYPHARM in connection with any work to
be performed under this Agreement has been debarred under Section 306(a) or (b) of the Act, and no debarred Person will in the future be employed or engaged by ETHYPHARM in connection with any work to be performed hereunder. 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 50 

 CONFIDENTIAL 
  

 (k) Suppliers and Subcontractors. Any and all suppliers of any goods or
services used in connection with the supply, manufacture, packaging, transport or handling of the Product, in whatever form and including any component or ingredient thereof, are and shall at all times during the Term hereof be in compliance with
all laws, rules, regulations, orders and similar requirements, including, without limitation, all Applicable Laws, and possess all Applicable Permits, in each case required to manufacture, package, transport, handle or otherwise deal with of the
Product or any component or ingredient thereof. 
  

	11.	TERM 

 11.1 Basic Term. Unless sooner
terminated pursuant to Section 11.2 hereof, this Agreement shall be effective from the date first above written and shall continue for an initial period of fifteen (15) years after the Launch Date of the Product in the United States
(i.e., February 2, 2020) (the “Initial Term”). Thereafter, the term of this Agreement shall automatically renew for consecutive periods of two (2) years each. Notwithstanding the foregoing, this Agreement may be
terminated by either party at the end of the Initial Term by delivery by such party to the other written notice at least one (1) year prior to the end of the Initial Term or at the end of any renewal term by delivery for such party to the other
written notice at least one hundred eighty (180) days prior to expiration of any renewal term. As used herein, “Term” refers to the Initial Term of this Agreement and any renewal terms. 
 11.2 Sale of Product Following Termination. Upon termination of this Agreement, ETHYPHARM shall supply, manufacture, sell and deliver to RELIANT
and RELIANT shall purchase from ETHYPHARM those firm orders for Product in existence as of the date of such 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 51 

 CONFIDENTIAL 
  

 
termination. RELIANT and its sublicensees shall have the right to dispose of existing inventory of Product, in whatever form, manufactured and delivered by
ETHYPHARM and purchased by RELIANT or its sublicensees prior to the termination (over a maximum period of twelve (12) months). Notwithstanding any termination of this Agreement, all licenses and rights granted to RELIANT hereunder shall
continue in full force and effect to allow RELIANT or its sublicensee(s) to dispose of any remaining Product on the termination date, and RELIANT shall be obligated to make royalty payments to ETHYPHARM as provided hereunder. 
  

	12.	EVENTS OF DEFAULT, REMEDIES AND EFFECTS OF DEFAULT 

 12.1 Events of Default. An event of default under this Agreement shall be deemed to exist upon the occurrence of any one or more of the following events (each, an “Event of Default”): 
 (a) failure by either party hereto to perform any covenant contained in this Agreement; 
 (b) a breach by either party of any material representation or warranty of such party under this Agreement; 
 (c) the entry by a court of competent jurisdiction of a decree or order of relief with respect to any party in any voluntary or
involuntary case or proceeding under any bankruptcy, insolvency or similar law, or the appointment of a receiver, liquidator, assignee, trustee or similar official of that party, which decree or order is consented to by the party or continues
unstayed and in effect for a period of sixty (60) days; 
 (d) the filing by any party of a voluntary petition or
acquiescence in or failure to contest an involuntary petition or an involuntary petition filed against such party that is not 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 52 

 CONFIDENTIAL 
  

 
dismissed within sixty (60) days, in any case or proceeding under any bankruptcy, insolvency or similar law, or the making by any party of an assignment
for the benefit of its creditors; or 
 (e) the involuntarily dissolution or liquidation of any party; provided, with
respect to any Event of Default under clause (a) or (b) above, such default continues (i) for a period of ninety (90) days after delivery by the non-defaulting party of written notice of such default, or (ii) if the
defaulting party shall commence good faith remediation of such default within such ninety (90) day period and shall thereafter proceed with all due diligence to cure such default, and such default is not cured within such longer period (not to
exceed ninety (90) days) as shall be reasonably necessary for such party to cure the same with all due diligence. 
 12.2 Remedies
for Breach; Termination. Upon the occurrence and during the continuation of any Event of Default hereunder, the party not in default may terminate this Agreement and pursue any other remedies provided under this Agreement or available at law or
equity. 
 12.3 Technology Transfer. In the event of any termination of this Agreement as a result of any Event of Default caused by
or related to any act or omission by or on behalf of ETHYPHARM or any of its Affiliates or agents, ETHYPHARM undertakes as a continuing obligation, notwithstanding such termination, that it will use all reasonable endeavors to effect a transfer of
the Intellectual Property and Confidential Information used by ETHYPHARM in the performance of its obligations hereunder to RELIANT or to a third-party manufacturer designated by RELIANT, and/or grant such licenses as may be necessary to enable
RELIANT or such third-party manufacturer to manufacture and package the Product in such form and quantities contemplated hereby for the Territory, subject at all times to ETHYPHARM receiving 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 53 

 CONFIDENTIAL 
  

 
reasonable undertakings as to confidentiality in respect of any ETHYPHARM Intellectual Property that is so transferred or licensed. 
 12.4 Right of First Offer In Connection with Divestiture. In the event RELIANT decides to divest the Product in the Territory, for whatever
reason, ETHYPHARM will be granted a right of first offer to acquire all rights in relation with the Product and the relevant Intellectual Property and Confidential Information belonging to RELIANT pursuant to terms no less favorable to ETHYPHARM
than those proposed to be offered third parties, such right to be exercised within a maximum period of [*] days from date of official written notification by RELIANT to ETHYPHARM. In the event ETHYPHARM does not exercise its right, RELIANT
undertakes to transfer to its assignee all rights and obligations vis-à-vis ETHYPHARM provided for in this Agreement. 
  

	13.	INDEMNIFICATION AND INSURANCE 

 13.1
Indemnification of RELIANT. ETHYPHARM shall indemnify and hold harmless RELIANT and its Affiliates and their respective equityholders, managers, directors, officers, trustees, agents and employees (collectively, “RELIANT Indemnified
Parties”) from and against all damages, losses, expenses, claims, demands, suits, penalties, judgments or administrative and judicial orders and liabilities (including reasonable legal fees and expenses) incurred, assessed or sustained by
any RELIANT Indemnified Party with respect to or involving or arising out of (i) a breach by ETHYPHARM of any representation, warranty, duty or covenant of ETHYPHARM hereunder, or (ii) any negligent act or omission, or willful misconduct
of ETHYPHARM or any of its Affiliates or agents. 
 13.2 Indemnification of ETHYPHARM. RELIANT shall indemnify and hold harmless
ETHYPHARM and its Affiliates and their respective equityholders, managers, directors, 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 54 

 CONFIDENTIAL 
  

 
officers, trustees, agents and employees (collectively, “ETHYPHARM Indemnified Parties”) from and against all damages, losses, expenses,
claims, demands, suits, penalties, judgments or administrative and judicial orders and liabilities (including reasonable legal fees and expenses) incurred, assessed or sustained by any ETHYPHARM Indemnified Party with respect to or involving or
arising out of (i) a breach by RELIANT of any representation, warranty, duty or covenant of RELIANT hereunder, or (ii) any negligent act or omission, or willful misconduct of RELIANT or any of its Affiliates or agents. 
 13.3 Notice and Legal Defense. Promptly after receipt by a party hereunder of any claim or notice of the commencement of any action,
administrative or legal proceeding, or investigation as to which the indemnity provided for in Section 13.1 and 13.2 hereof may apply, the party seeking indemnification shall notify the indemnifying party of such fact. The
indemnifying party shall assume the defense thereof; provided, however, that if the defendants in any such action include both the party seeking indemnification and the indemnifying party and the party seeking indemnification shall reasonably
conclude that there may be legal defenses available to it which are different from or additional to, or inconsistent with, those available to the indemnifying party, the party seeking indemnification shall have the right to select separate counsel
(reasonably acceptable to the indemnifying party) to participate in the defense of such action on behalf of such party seeking indemnification, at the indemnifying party’s expense. 
 13.4 Insurance. Each party shall, at its own cost, cause the other party and its respective agents, employees, officers, shareholders and
contractors to be added as additional insureds on all policies of general commercial liability insurance and product liability insurance covering such party, which coverage shall have limits of liability which are commercially reasonable but shall
not be less than US$[*] per loss occurrence. Each policy shall contain an 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 55 

 CONFIDENTIAL 
  

 
endorsement which provides that any amendments or cancellation of any such policy shall not be effective unless the other party shall have been given thirty
(30) days prior written notice of any such intended amendment or cancellations. Within five (5) days of the beginning of each policy period, each party shall deliver to the other a certificate evidencing the coverage required hereby and
the amount thereof. Such coverage shall be maintained for not less than five (5) years following termination of this Agreement or if such coverage is of the “claims made” type, for [*] years following termination of this Agreement.

  

	14.	ETHYPHARM RIGHTS IN CANADA AND MEXICO 

 14.1
Reversion of Canadian and Mexican Rights. In connection herewith, the parties have agreed that the Territory shall no longer include Canada and Mexico, such that ETHYPHARM hereby reacquires from RELIANT all licenses, rights, title and
interest of RELIANT under the Original Agreement in respect of such countries; provided, however, that ETHYPHARM shall not have any right, either directly or indirectly, to market, promote, sell, commercialize or otherwise exploit the Product
in Canada or Mexico unless and until the Additional Manufacturing Facility is fully established, validated and certified in accordance with Section 5.4, such that such RELIANT may accept delivery of, import, package, market, sell and
otherwise commercialize any Product manufactured at such Additional Manufacturing Facility in the Territory; provided, further, that nothing in this Article 14 gives or shall be deemed to give ETHYPHARM the right to make, or cause to
be made, any regulatory or similar filings in any jurisdiction in the Territory. 
 14.2 ETHYPHARM Right to RELIANT Clinical Data for
Canada and Mexico. Notwithstanding the provisions of Section 2.3, RELIANT shall grant ETHYPHARM access to the RELIANT Clinical Data for use solely in Canada and Mexico in order that ETHYPHARM 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 56 

 CONFIDENTIAL 
  

 
may use such RELIANT Clinical Date for the limited purpose of obtaining registrations with the appropriate Canadian and Mexican regulatory authorities in
order to allow ETHYPHARM to commercialize the Product in such country. ETHYPHARM agrees that any reference to RELIANT Clinical Data (including by means of reference to any Canadian or Mexican registrations) for use in any other country other than
Canada and Mexico shall be subject to the provisions of Section 2.3. 
 14.3 Royalties on Sales of Product in Canada and
Mexico. In consideration of the reversion of rights in Canada and Mexico and the right to use RELIANT Clinical Data in such countries, ETHYPHARM agrees to pay to RELIANT a royalty, net of any Taxes required to be withheld therefrom, in the
amount equal to [*] percent ([*]%) of Net Sales of the Product and/or any Competing Dosage Form sold in Canada or Mexico (collectively, the “Canadian/Mexican Product”), which royalty payments shall be made in accordance with the
provisions of this Agreement applicable to royalty payments payable by RELIANT to ETHYPHARM. For the purposes of this Section 14.3, the definition of the term “Net Sales” under Section 1 shall be read to refer to
amounts invoiced by or on behalf of ETHYPHARM (including any of its Affiliates, assignees or licensees) for the Canadian/Mexican Product, rather than RELIANT, and the reference therein to Territory shall be deemed to be Canada and Mexico.
Notwithstanding any provision herein to the contrary, RELIANT’s right to receive royalty payments under this Section 14.3 may be separately assigned by RELIANT to any of its Affiliates or third parties separate and apart from any
assignment or sublicences of any other license or right of RELIANT hereunder. With respect to any Combination Products to be developed or commercialized by ETHYPHARM in Canada or Mexico, the parties shall negotiate in good faith the specific terms
and conditions relating thereto (including any royalties in respect of sales thereof in Canada 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 57 

 CONFIDENTIAL 
  

 
and/or Mexico), which shall be set forth in a separate agreement to be negotiated and executed by ETHYPHARM and RELIANT. 
 14.4 Certain Restrictions on Commercialization in Canada and Mexico. In addition, in consideration of the reversion of rights in Canada and Mexico
and the right to use RELIANT Clinical Data in such countries, ETHYPHARM agrees that (a) neither ETHYPHARM nor any of its Affiliates, assignees, licensees or distributors shall sell, distribute or otherwise commercialize any Canadian/Mexican
Product under the trademark “Antara®” or
any other a trademark or tradedress confusingly similar to those being used by RELIANT for the Product and/or any Competing Dosage Form in the United States; and (b) ETHYPHARM shall not, and shall cause each of its Affiliates, assignees,
licensees and distributors not to, (i) market, distribute or sell any Canadian/Mexican Product or any pharmaceutical product containing micronized fenofibrate as an active ingredient within the Territory, (ii) knowingly cause or facilitate
any Canadian/ Mexican Product to be marketed, distributed, or sold within the Territory, except by or on behalf of RELIANT pursuant to this Agreement, and (iii) market, distribute or sell any Canadian/Mexican Product outside the Territory to a
third party who ETHYPHARM or any of its Affiliates, assignees, licensees and distributors knows intends to distribute such products within the Territory, (iv) knowingly supply any bulk API to any third party for ultimate sale and/or
distribution in the Territory, or (v) market, sell, distribute, or manufacture generic micronized fenofibrate for any other Person in the Territory, which restrictions shall survive any termination of this Agreement. In the event that RELIANT
can reasonably demonstrate that any Canadian/Mexican Product manufactured by or on behalf of ETHYPHARM under this Section 14 is being sold or otherwise entering the Territory, ETHYPHARM shall reimburse 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 58 

 CONFIDENTIAL 
  

 
RELIANT an amount sufficient to compensate RELIANT for the profits pertaining to the lost sales of the Product by RELIANT in the Territory as a result
thereof. 
  

	15.	MISCELLANEOUS 

 15.1 Assignment.

 (a) Subject to Section 15.1(b), below, this Agreement shall be binding upon and shall inure to the benefit of
the parties hereto and their respective successors and assigns permitted under this Agreement. 
 (b) Neither party may assign
this Agreement or any of its rights hereunder or delegate its performance of its obligations hereunder without the express prior written consent of the other party, except that either party may assign or delegate any of its rights or obligations
under this Agreement to an Affiliate or subsidiary of the assigning party; provided that the assigning party shall, by express written agreement, (i) remain liable for any obligations and liabilities incurred by it under this Agreement,
and (ii) be made liable for all obligations and liabilities of the assignee following such assignment; provided, further, that the assignee shall expressly acknowledge, by written agreement, its assumption of all obligations and
liabilities under this Agreement. Any attempted assignment in violation of this provision shall be deemed a material breach of this Agreement. 
 For
purposes of this Section 15.1, a transfer to an unaffiliated third party, by either RELIANT or ETHYPHARM, of all or substantially all of its assets or a controlling interest in its stock or other equity interests, shall be deemed an
assignment; provided that, any of the following shall not be deemed an assignment and shall be permitted without consent from ETHYPHARM or RELIANT, as applicable, thereto: (1) any conversion in the type of legal entity of RELIANT
(i.e., from a corporation to a limited liability company); (2) any issuance by RELIANT or 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 59 

 CONFIDENTIAL 
  

 
ETHYPHARM of securities in connection with any financing transaction or public offering, (3) any acquisition or merger involving RELIANT or ETHYPHARM if
the acquiring or surviving company is a reputable company engaged in the pharmaceutical business with a history of substantial regulatory compliance, and/or (4) any merger or acquisition to which the other party hereto has given its prior
written consent. Nothing herein shall preclude RELIANT from sublicensing any or all of its rights hereunder in accordance with the terms of this Agreement, or from entering into agreements with third parties to co-promote or assist RELIANT in the
sale, marketing or promotion of the product provided that the foregoing shall not relieve RELIANT of any of its obligations hereunder. 
 15.2 Confidentiality. Each party will hold Confidential Information of the other party and its Affiliates in complete confidence and will not, without the prior written consent of the other, use or disclose it in whole or in part to
any Person other than for the purposes set forth in this Agreement for a period ending five (5) years following expiration of this Agreement. Each party will be entitled to disclose any such Confidential Information to such of its professional
advisers, directors, managers, officers and employees who are directly concerned with this Agreement and its implementation and whose knowledge of such information in the opinion of the disclosing party is necessary for these purposes. Each party
will use its reasonable efforts to ensure that each individual to whom such a disclosure is made adheres to the terms of this undertaking as if he or she were a party hereto. Each party may disclose such Confidential Information to the extent such
disclosure is required by law; provided, however, that the disclosing party shall (to the extent permitted) give the other party prior notice of such required disclosure and cooperate with such other party in order that such other party may
seek a protective order or relief to prevent or limit the Confidential Information required to be 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 60 

 CONFIDENTIAL 
  

 
disclosed; provided, further, that the disclosing party shall only disclose that portion of the Confidential Information that such party is advised by
its legal counsel is required to be disclosed by law and shall seek assurances that such Confidential Information will be maintained in confidentiality by the receiving party. 
 15.3 Exchange of Information. RELIANT will periodically inform ETHYPHARM with information regarding unit sales by market region in the Territory.
Each party will timely report to the other any information concerning any serious adverse event (as defined by the Act) associated with clinical uses, studies, investigations or tests of the Product, whether in Bulk Product Form or in Finished
Dosage Form. In reporting such incidents, the reporting party will use reasonable efforts to indicate whether, in its judgment, any of them are unexpected or unusual in type, incidence or severity. 
 15.4 Force Majeure. If either party is prevented from complying, either totally or in part, with any of the terms or provisions set forth herein
by reason of force majeure, including, by way of example and not of limitation, fire, flood, explosion, storm, strike, lockout or other labor dispute, riot, war, rebellion, accidents, acts of God, acts of Governmental Authorities, failure of
suppliers or any other similar cause, in each case to the extent beyond its reasonable control, said party will provide written notice of same to the other party. Said notice will be provided within five (5) Business Days of the occurrence of
such event and will identify the requirements of this Agreement or such of its obligations as may be affected, and to the extent so affected, said obligations will be suspended during the period of such disability. If any raw materials, facility
systems or capacity is used for both the manufacture and packaging of the Product in satisfaction of ETHYPHARM’s obligations hereunder and any other product or purposes, any necessary allocation will be made as between ETHYPHARM’s needs,
RELIANT’s 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 61 

 CONFIDENTIAL 
  

 
needs and the needs of any other party with whom ETHYPHARM has firm contractual obligations on a basis no less favorable than pro rata on a volume basis. The
party prevented from performing hereunder will use its commercially reasonable efforts to remove such disability and will continue performance whenever such causes are removed. The party so affected will give to the other party a good faith estimate
of the continuing effect of the force majeure condition and the duration of the affected party’s nonperformance. If the period of any previous actual nonperformance of ETHYPHARM because of ETHYPHARM force majeure conditions plus
the anticipated future period of ETHYPHARM nonperformance because of such conditions will exceed an aggregate of ninety (90) days within any six (6) month period, RELIANT may terminate this Agreement immediately by written notice to
ETHYPHARM. If the period of any previous actual nonperformance of RELIANT because of RELIANT force majeure conditions plus the anticipated future period of RELIANT nonperformance because of such conditions will exceed an aggregate of ninety
(90) days within any six (6) month period, ETHYPHARM may terminate this Agreement immediately by written notice to RELIANT. When such circumstances as those contemplated herein arise, the parties will discuss in good faith, what, if any,
modification of the terms set forth herein may be required in order to arrive at an equitable solution. 
 15.5 Amendment. No
amendment or modification of the terms of this Agreement shall be binding on either party unless in writing and signed by both parties. 
 15.6 No Implied Waiver. Failure by either party hereto on one or more occasions to avail itself of a right conferred by this Agreement shall in no event be construed as a waiver of such party’s right to enforce said right in the
future. 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 62 

 CONFIDENTIAL 
  

 15.7 Choice of Law. This Agreement and all rights and obligations hereunder, including matters
of construction, validity and performance, shall be governed by and construed in accordance with the laws of the state of New Jersey, without giving effect to the conflict of laws principles thereof. 
 15.8 CONSENT TO JURISDICTION; AGENT FOR SERVICE OF PROCESS. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AGREES THAT ANY SUIT, ACTION, PROCEEDING
OR CLAIM AGAINST SUCH PARTY ARISING OUT OF OR IN ANY WAY RELATING TO THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY, OR ANY JUDGMENT ENTERED BY ANY COURT IN RESPECT THEREOF, MAY BE BROUGHT OR ENFORCED IN THE STATE OR FEDERAL COURTS
LOCATED IN THE COUNTY OF SOMERSET IN THE STATE OF NEW JERSEY AND THE COMPANY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE VENUE OF ANY PROCEEDING BROUGHT IN THE COUNTY OF
SOMERSET IN THE STATE OF NEW JERSEY AND FURTHER IRREVOCABLY WAIVES ANY CLAIMS THAT ANY SUCH PROCEEDING HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. ETHYPHARM HEREBY IRREVOCABLY AND UNCONDITIONALLY APPOINTS BAACH ROBINSON & LEWIS PLLC, 1201 F
STREET, NW, SUITE 500, WASHINGTON, DC 20004 (ATTENTION: DWIGHT P. BOSTWICK AND BRUCE R. GRACE), AS AGENT FOR SERVICE OF PROCESS UNDER THIS AGREEMENT. 
 15.9 WAIVER OF JURY TRIAL. THE PARTIES HERETO HEREBY EXPRESSLY WAIVE ANY RIGHT TO A TRIAL BY JURY IN ANY ACTION OR PROCEEDING TO ENFORCE OR DEFEND ANY RIGHT, POWER, OR REMEDY UNDER OR IN 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 63 

 CONFIDENTIAL 
  

 
CONNECTION WITH THIS AGREEMENT OR ANY OF THE RELATED AGREEMENTS OR UNDER OR IN CONNECTION WITH ANY AMENDMENT, INSTRUMENT, DOCUMENT, OR AGREEMENT DELIVERED OR
WHICH MAY IN THE FUTURE BE DELIVERED IN CONNECTION HEREWITH OR THEREWITH OR ARISING FROM ANY RELATIONSHIP EXISTING IN CONNECTION WITH THIS AGREEMENT OR ANY RELATED AGREEMENT, AND AGREE THAT ANY SUCH ACTION SHALL BE TRIED BEFORE A COURT AND NOT
BEFORE A JURY. THE TERMS AND PROVISIONS OF THIS SECTION CONSTITUTE A MATERIAL INDUCEMENT FOR THE PARTIES ENTERING INTO THIS AGREEMENT. 
 15.10 Notice. Any notice and other communication required or permitted to be given hereunder shall be in writing and shall be deemed given when delivered personally, telecopied or received by registered mail, return receipt
requested, or from an internationally-recognized courier service to the parties at the following addresses: 
 if to ETHYPHARM, to:

 ETHYPHARM S.A. 
 194, Bureaux
de la Colline – Bâtiment D 
 92213 Saint Cloud 
 France 
 Attn: Gérard M. Leduc, Managing Director 
 Fax:   +33 1 41 12 29 89 
 with copies sent simultaneously to: 
 Baach Robinson & Lewis PLLC 
 1201 F Street, NW 
 Suite 500 
 Washington, DC 20004 
 Attn: Dwight P.
Bostwick and Bruce R. Grace 
 Fax:   +1 (202) 466-5738 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 64 

 CONFIDENTIAL 
  

 if to RELIANT, to: 
 RELIANT PHARMACEUTICALS, INC. 
 110 Allen Road 
 Liberty Corner, New Jersey 07938 
 USA

 Attn.: Joseph Zakrweski and Michael Lerner 
 Fax:   +1 (908) 542-9405 
 with a copy sent simultaneously to: 
 Latham & Watkins LLP 
 Sears Tower,
Suite 5800 
 Chicago, Illinois 60606 
 USA 
 Attn: Michael A. Pucker and Thomas E. Keim, Jr. 
 Fax:   +1 (312) 993-9767 
 15.11 English Language. This Agreement and all
exhibits, schedules, reports, notices and all other communications and proceedings with respect hereto shall be written and/or conducted solely in the English language. 
 15.12 Execution of Additional Documents. Each party hereto agrees to execute such further documents or agreements as may be reasonably necessary or desirable to effect the purpose of this Agreement and carry
out its provisions. 
 15.13 Severability. In the event that any provision of this Agreement shall be held invalid or unenforceable by
any court of competent jurisdiction, such holding shall not invalidate or render unenforceable any other provision hereof. 
 15.14
Captions. The article and section captions in this Agreement have been inserted as a matter of convenience and are not part of this Agreement. 
 15.15 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original of this Agreement and all of which together shall constitute one and the same
instrument. 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 65 

 CONFIDENTIAL 
  

 15.16 Independent Relationship. Nothing herein contained shall be deemed to create an
employment, agency, joint venture or partnership relationship between the parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one party for the act or failure to act of the other party.
Neither party shall have any power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other or to bind the other party in any respect whatsoever. All activities undertaken by ETHYPHARM
hereunder shall be that of an independent contractor. 
 15.17 Entire Agreement. This written Agreement, together with all exhibits,
schedules and attachments hereto or referenced herein, constitutes the entire understanding between the parties hereto relating to the subject matter hereof and supersedes and replaces all prior and contemporaneous agreements relating thereto,
including, without limitation, the Original Agreement (excluding any exhibits or schedules thereto specifically incorporated herein by reference). No variation or modification of this Agreement or waiver of any of the terms or provisions hereof
shall be deemed valid unless in writing and signed by both parties hereto. 
 15.18 Continued Obligation. During the pendency of any
bona fide dispute, the parties shall continue to perform their respective obligations under this Agreement until such time as (a) the matter in dispute is finally resolved or (b) this Agreement is terminated in accordance with its terms.

 15.19 Survival. The provisions of Sections 6, 7.7, 7.8, 7.9, 7.11, 11.2, 12.2,
13, 15.2, 15.7, 15.8, 15.9, 15.10 and 15.11, shall survive and remain in effect after termination or expiration of this Agreement. 
 (Signature page follows.) 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

  

 66 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized
representatives as of the day and year first above written. 
  

			
	ETHYPHARM S.A.
		
	By:	 	/s/ Gerard Leduc
		 	Name: Gerard Leduc
		 	Title: President and CEO

  

			
	RELIANT PHARMACEUTICALS, INC.
		
	By:	 	/s/ Joseph Zakrewski
		 	Name: Joseph Zakrewski
		 	Title: CEO

  

			
	Acceptance and acknowledgment of appointment by Baach Robinson & Lewis as its agent for service of process under Section 15.8 of this Agreement:
	
	Baach Robinson & Lewis PLLC
		
	By:	 	/s/ Dwight P. Bostwick
		 	Name: Dwight P. Bostwick
		 	Title:

 SIGNATURE PAGE TO AMENDED AND RESTATED 
 DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 CONFIDENTIAL 
  

 SCHEDULE OF PATENTS 
 Patents 
 [*] [One Page Omitted]. 
  

	[*] =	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.First Amendment Agreement

 EXHIBIT 10.1 
 FIRST AMENDMENT AGREEMENT 
 among 
 QC HOLDINGS, INC., as Borrower 
 and 
 THE BANKS THAT ARE PARTIES HERETO 
 and 
 U.S. BANK NATIONAL ASSOCIATION, as Agent and Arranger 
 OCTOBER 30, 2006 
  

 1 

 FIRST AMENDMENT AGREEMENT 
 This First Amendment Agreement (this “Agreement”), is made and entered into as of October 30, 2006, by and between QC HOLDINGS, INC., a
Kansas corporation (the “Borrower”), the Banks that are parties hereto (being hereinafter referred to individually as a “Bank” or collectively as the “Banks”), and U. S. BANK NATIONAL ASSOCIATION, in its capacity as
Agent (the “Agent”). 
 RECITALS 
 A. On January 19, 2006, the Borrower, the Banks and the Agent entered into a Credit Agreement (the “Credit Agreement”) pursuant to which the Banks agreed to make a revolving credit facility available to the Borrower, and in
conjunction therewith, the Borrower executed certain Promissory Notes (Revolving Loan) payable to the Banks, each dated January 19, 2006 (the “Notes”). 
 B. The repayment of the Notes is secured by certain assets of the Borrower and its Subsidiaries referred to as the “Collateral” in the Credit Agreement, which is more particularly described in the Security
Agreement, the Pledge Agreements and the Subsidiary Security Agreements (as each term is defined in the Credit Agreement), each dated as of January 19, 2006 (collectively, the “Security Instruments”). 
 C. The Borrower acknowledges (i) the Banks are presently the holders of the Notes, (ii) the Borrower’s liability to pay the Notes according to their
terms, and (iii) the Borrower’s obligation to maintain, perform and comply with the terms and conditions of the Loan Documents (as such term is defined in the Credit Agreement). 
 D. The Borrower, the Agent and the Banks acknowledge that the Borrower will likely fail to maintain the required Fixed Charge Coverage Ratio referenced in
Section 7.02(b) of the Credit Agreement as of the determination date of September 30, 2006 (the “Anticipated Default”). 
 E. The parties
enter into this Agreement to amend certain terms and conditions of the Credit Agreement and to provide for the waiver by the Agent and the Banks of the Anticipated Default. 
 NOW THEREFORE, the Agent, the Banks and the Borrower for good, sufficient and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, agree as follows: 
 1. Amendments to the Credit Agreement. The Credit Agreement is amended as follows: 
 (a) The definition of the term “Distributions” contained in Section 1.01 is deleted and the following definition is inserted in lieu
thereof: 
 “Distribution” means any declaration, payment or setting apart of any sum for payment of any
dividend (except a dividend payable in common stock of the Borrower) on, or any distribution (except a distribution in common stock of the Borrower) in respect of, any shares of capital stock of the Borrower. 
  

 2 

 (b) The definition of “Operating Cash Flow” contained in Section 1.01 is deleted and the
following definition is inserted in lieu thereof: 
 “Operating Cash Flow” means, for the determination
period, the sum of (i) EBITDA, plus (ii) Operating Lease Expense, minus (iii) Maintenance Capital Expenditures, minus (iv) Income Tax Expense, minus (v) the value or amount of a Distribution. 
 (c) The definition of the term “Restricted Payment” contained in Section 1.01 is deleted. 
 (d) A definition of the term “Cash Operating Expenses” is added to Section 1.01 as follows: 
 “Cash Operating Expenses” means the sum of Regional Expenses and Corporate Expenses, as each such item is shown on the
financial statements of the Borrower. 
 (e) The provision contained in Subsection 7.02(k) is deleted and the following provision is inserted
in lieu thereof: 
 (k) Restricted Payments. Make or commit to make (i) any Distribution if a Default or Event of
Default has occurred and is continuing or would result from the proposed Distribution, or (ii) the redemption, repurchase, retirement or other acquisition of (or the setting apart of any sum in respect of any of the foregoing actions) shares of
capital stock of the Borrower or warrants, rights or options to purchase or acquire shares of any capital stock of the Borrower (other than an exchange of capital stock of the Borrower for other shares of capital stock of the Borrower) if, a Default
or Event of Default has occurred and is continuing or would result from any of the foregoing, or would result in the redemption, repurchase, retirement, acquisition of shares of capital stock or a warrant, right or option to purchase shares of
capital stock in an aggregate amount in excess of $30,000,000.00 from and after July 14, 2004. 
 (f) The following provision is added
as Subsection 7.02(o): 
 (o) Amendment to or Creation of Stock Repurchase Program. Make any modification or amendment
to its existing stock repurchase program to increase the aggregate authorization for stock repurchases to an amount in excess of $30,000,000.00 or create or institute any new stock repurchase program. 
 (g) The following provision is added as Subsection 7.02(p): 
 (p) Redemption of Stock. Prior to the redemption, repurchase, retirement or acquisition of capital stock or the issuance of any warrant, 
  

 3 

 right or option to purchase or acquire capital stock in a transaction that exceeds $1,000,000.00, the
Borrower shall provide to the Agent pro forma financial statements as of the end of the most recently completed fiscal quarter (together with calculation of the financial covenants contained in Section 7.02 and a calculation of the minimum
liquidity of the Borrower as referenced in item (ii) below), in form and content acceptable to the Agent, which evidence that the making or committing to make any of the foregoing actions will not result in (i) a violation of any financial
covenant contained in Section 7.02 of this Agreement or (ii) the sum of the amount available to lend as shown on the most recent Borrowing Base Certificate plus the amount of cash and Cash Equivalents owned by the Borrower and its
Subsidiaries which are not included in the Borrowing Base to be less than six (6) months of Cash Operating Expenses. 
 3. Conditions
Precedent. It shall be a condition precedent to the effectiveness of this Agreement that (i) all amounts due and payable under the Notes as of the execution date shall have been paid, (ii) no Event of Default (other than the
Anticipated Default) shall exist under the Notes, the Credit Agreement, or any other Loan Document, and (iii) the Agent shall have received such other items as they may reasonably request. 
 4. Representations and Warranties. The Borrower hereby represents and warrants that (i) it has the authority to enter into this Agreement
and, upon execution by the Borrower, this Agreement shall be an enforceable obligation of the Borrower, (ii) all representations and warranties made by the Borrower in the Credit Agreement and the other Loan Documents are true and correct as of
the date of this Agreement, (iii) there have been no amendments or modifications to the Borrower’s organizational documents since such documents were certified and/or delivered to the Lender in connection with the closing of the Loan and
(iv) no Default or Event of Default (other than the Anticipated Default) currently exists under the Loan Documents. 
 5. No Other
Amendments. Except as expressly set forth herein, or necessary to incorporate the modifications and amendments herein, all the terms and conditions of the Notes, the Credit Agreement, the Security Instruments, and the other Loan Documents shall
remain unmodified and in full force and effect, and the Borrower confirms, reaffirms and ratifies all such documents and agrees to perform and comply with the terms and the conditions of the Loan Documents, as amended herein. 
 6. No Impairment. Nothing in this Agreement shall be deemed to or shall in any manner prejudice or impair the Loan Documents, or any security
granted or held by the Banks for the indebtedness evidenced by the Notes. 
 7. Waiver of Anticipated Default. The Agent and the Banks
hereby waive, in advance, any rights or remedies to which they may be entitled on account of the actual occurrence of the Anticipated Default. This waiver is a one-time waiver and shall not result in a waiver with respect to any other Default or
Event of Default which may now or hereafter exist or obligate the Agent or the Banks to issue a waiver of a Default or Event of Default arising in the future. 
 8. Binding Agreement. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns. 
  

 4 

 9. Applicable Law. This Agreement shall be governed by and construed in accordance with the
internal laws of the State of Kansas. 
 10. Waiver of Claims and Defenses. The Borrower hereby waives and releases any and all
claims, defenses or rights of set-off, known or unknown, existing as of the execution date, which in any manner arise out of or relate to any Loan Document. 
 11. Fees and Expenses. The Borrower agrees to pay and reimburse the Agent for all of its out-of-pocket costs and expenses incurred in connection with the preparation, negotiation, execution, filing, enforcement
and administration of this Agreement including, without limitation, the fees and expenses of counsel to the Agent. 
 12.
Counterparts. This Agreement may be executed in counterparts and when combined all such counterparts shall constitute one agreement. 
 13. Waiver of Jury Trial. Any controversy or claim between or among the parties hereto arising out of or relating to this Agreement shall be controlled by the provisions with respect to waiver of trial by jury contained in the Loan
Documents previously delivered by such parties. 
 14. NO ORAL AGREEMENTS. THIS IS THE FINAL EXPRESSION OF THE CREDIT AGREEMENT
BETWEEN THE BORROWER, THE AGENT AND THE BANKS AND SUCH WRITTEN CREDIT AGREEMENT MAY NOT BE CONTRADICTED BY EVIDENCE OF ANY PRIOR ORAL AGREEMENT OR OF A CONTEMPORANEOUS ORAL CREDIT AGREEMENT BETWEEN THE BORROWER, THE AGENT AND BANKS. 
  

 5 

 ANY ADDITIONAL NON-STANDARD TERMS OF THE CREDIT AGREEMENT AND THE REDUCTION TO WRITING OF ANY PREVIOUS
ORAL CREDIT AGREEMENT BETWEEN THE BORROWER, THE AGENT AND BANKS IS SET FORTH IN THE SPACE BELOW: 
 NONE 
 BORROWER, THE AGENT AND BANKS AFFIRM THAT NO UNWRITTEN ORAL CREDIT AGREEMENT BETWEEN THEM EXISTS. 
 Please initial  
                                       
                                       
                                       

________________    ____________         
 ________________    ____________         
 [SIGNATURES APPEAR ON FOLLOWING PAGES] 
  

 6 

 IN WITNESS WHEREOF, the Agent, the Borrower and the Banks have executed this Agreement as of the day and
year first above written. 
  

			
	AGENT:
	
	U.S. BANK NATIONAL ASSOCIATION
		
	By:	 	 /s/ Timothy Petty

		 	Timothy Petty
		 	Senior Vice President

  

 7 

 IN WITNESS WHEREOF, the Agent, the Borrower and the Banks have executed this Agreement as of the day and
year first above written. 
  

			
	BORROWER:
	
	 QC HOLDINGS, INC.,
 a Kansas
corporation

		
	By:	 	 /s/ Douglas E. Nickerson

		 	Douglas E. Nickerson
		 	Chief Financial Officer

  

 8 

 IN WITNESS WHEREOF, the Agent, the Borrower and the Banks have executed this Agreement as of the day and
year first above written. 
  

			
	BANKS:
	
	U. S. BANK NATIONAL ASSOCIATION
		
	By:	 	 /s/ Timothy Petty

		 	Timothy Petty
		 	Senior Vice President

  

 9 

 IN WITNESS WHEREOF, the Agent, the Borrower and the Banks have executed this Agreement as of the day and
year first above written. 
  

			
	BANKS:
	
	BANK MIDWEST, N.A.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

  

 10 

 IN WITNESS WHEREOF, the Agent, the Borrower and the Banks have executed this Agreement as of the day and
year first above written. 
  

			
	 BANKS:

	
	ENTERPRISE BANK & TRUST
		
	By:	 	  

	Name:	 	  

	Title:	 	  

  

 11 

 IN WITNESS WHEREOF, the Agent, the Borrower and the Banks have executed this Agreement as of the day and
year first above written. 
  

			
	BANKS:
	
	BANK OF OKLAHOMA, N.A.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

  

 12 

 IN WITNESS WHEREOF, the Agent, the Borrower and the Banks have executed this Agreement as of the day and
year first above written. 
  

			
	BANKS:
	
	NATIONAL CITY BANK
		
	By:	 	  

	Name:	 	  

	Title:	 	  

  

 13 

 ACKNOWLEDGMENT AND AGREEMENT OF GUARANTORS/PLEDGORS 
 Each of the undersigned guarantors and/or pledgors of collateral with respect to the obligations of the Borrower to the Agent and the Banks hereby
(i) acknowledge and consent to the terms of the foregoing First Amendment Agreement, (ii) represents and warrants to the Agent and the Banks that there exists no default or event of default under any document delivered by it to the Agent
or the Banks with respect to the Loan and (iii) reaffirms and ratifies the full force and effect of any guaranty agreement or security instrument delivered by it in connection with the Loan. 
  

			
	QC Financial Services, Inc.,
	a Missouri corporation
		
	By:	 	 /s/ Douglas E. Nickerson

		 	Douglas E. Nickerson
		 	Chief Financial Officer
	
	 QC Properties, LLC,
 a Kansas limited
liability company

		
	By:	 	 /s/ Don Early

		 	Don Early
		 	Manager
	
	 QC Financial Services of California, Inc.,
 a
California corporation

		
	By:	 	 /s/ Douglas E. Nickerson

		 	Douglas E. Nickerson
		 	Chief Financial Officer

  

 14 

			
	QC Financial Services of Texas, Inc.,
	a Kansas corporation
		
	By:	 	 /s/ Douglas E. Nickerson

		 	Douglas E. Nickerson
		 	Chief Financial Officer
	
	 QC Advance, Inc.,
 a Missouri
corporation

		
	By:	 	 /s/ Douglas E. Nickerson

		 	Douglas E. Nickerson
		 	Chief Financial Officer
	
	 Cash Title Loans, Inc.,
 a Missouri
corporation

		
	By:	 	 /s/ Douglas E. Nickerson

		 	Douglas E. Nickerson
		 	Chief Financial Officer

  

 15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}]]